



HU000034781T2

(19) **HU**(11) Lajstromszám: **E 034 781**(13) **T2****MAGYARORSZÁG**
Szellemi Tulajdon Nemzeti Hivatala**EURÓPAI SZABADALOM**
SZÖVEGÉNEK FORDÍTÁSA

- (21) Magyar ügyszám: **E 10 703495**
- (22) A bejelentés napja: **2010. 02. 10.**
- (96) Az európai bejelentés bejelentési száma:
EP 20100703495
- (97) Az európai bejelentés közzétételi adatai:
EP 2396410 A1 **2010. 08. 19.**
- (97) Az európai szabadalom megadásának meghirdetési adatai:
EP 2396410 B1 **2017. 03. 15.**
- (51) Int. Cl.: **C12N 15/12** (2006.01)
C07K 16/00 (2006.01)
C12N 9/02 (2006.01)
C12P 21/02 (2006.01)
C12N 15/13 (2006.01)
C12N 15/53 (2006.01)
C07K 14/47 (2006.01)
- (86) A nemzetközi (PCT) bejelentési szám:
PCT/GB 10/000234
- (87) A nemzetközi közzétételi szám:
WO 10092335

(30) Elsőbbségi adatok: 0902180 2009. 02. 10. GB	(73) Jogosult(ak): UCB Biopharma SPRL, 1070 Brussels (BE)
(72) Feltaláló(k): CAIN, Katharine, Lacy, Slough Berkshire SL1 3WE (GB) PETERS, Shirley, Jane, Slough Berkshire SL1 3WE (GB) STEPHENS, Paul, Edward, Slough Berkshire SL1 3WE (GB)	(74) Képvisező: Danubia Szabadalmi és Jogi Iroda Kft., Budapest

(54) **Eljárás fehérje előállítására**

Az európai szabadalom ellen, megadásának az Európai Szabadalmi Közlönyben való meghirdetésétől számított kilenc hónapon belül, felszólalást lehet benyújtani az Európai Szabadalmi Hivatalnál. (Európai Szabadalmi Egyezmény 99. cikk(1))

A fordítást a szabadalmat az 1995. évi XXXIII. törvény 84/H. §-a szerint nyújtotta be. A fordítás tartalmi helyességét a Szellemi Tulajdon Nemzeti Hivatala nem vizsgálta.



(11) **EP 2 396 410 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention of the grant of the patent:
15.03.2017 Bulletin 2017/11

(21) Application number: **10703495.1**

(22) Date of filing: **10.02.2010**

(51) Int Cl.:
C12N 15/12 (2006.01) **C12N 15/13** (2006.01)
C12N 15/53 (2006.01) **C12N 9/02** (2006.01)
C07K 14/47 (2006.01) **C12P 21/02** (2006.01)
C07K 16/00 (2006.01)

(86) International application number:
PCT/GB2010/000234

(87) International publication number:
WO 2010/092335 (19.08.2010 Gazette 2010/33)

(54) **METHOD FOR PRODUCING PROTEIN**
PROTEINHERSTELLUNGSMETHODE
PROCÉDÉ DE PRODUCTION DE PROTÉINE

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR
Designated Extension States:
BA RS

(30) Priority: **10.02.2009 GB 0902180**

(43) Date of publication of application:
21.12.2011 Bulletin 2011/51

(73) Proprietor: **UCB Biopharma SPRL**
1070 Brussels (BE)

(72) Inventors:
• **CAIN, Katharine, Lacy**
Slough
Berkshire SL1 3WE (GB)
• **PETERS, Shirley, Jane**
Slough
Berkshire SL1 3WE (GB)
• **STEPHENS, Paul, Edward**
Slough
Berkshire SL1 3WE (GB)

(74) Representative: **Thompson, John**
UCB Celltech,
208 Bath Road
Slough, Berkshire SL1 3WE (GB)

(56) References cited:
WO-A1-99/07727 **WO-A1-2006/067511**

WO-A2-03/089622 **WO-A2-2004/111194**
WO-A2-2006/028889 **WO-A2-2008/115596**

- **MEZGHRANI A ET AL:** "Manipulation of oxidative protein folding and PDI redox state in mammalian cells." THE EMBO JOURNAL 15 NOV 2001 LNKD-PUBMED:11707400, vol. 20, no. 22, 15 November 2001 (2001-11-15), pages 6288-6296, XP002579437 ISSN: 0261-4189
- **YOSHIDA H ET AL:** "XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor" CELL, CELL PRESS, CAMBRIDGE, NA, US LNKD- DOI:10.1016/S0092-8674(01)00611-0, vol. 107, 28 December 2001 (2001-12-28), pages 881-891, XP002974245 ISSN: 0092-8674
- **LEE ANN-HWEE ET AL:** "XBP-1 regulates a subset of endoplasmic reticulum resident chaperone genes in the unfolded protein response." MOLECULAR AND CELLULAR BIOLOGY NOV 2003 LNKD- PUBMED:14559994, vol. 23, no. 21, November 2003 (2003-11), pages 7448-7459, XP002579438 ISSN: 0270-7306
- **GUNN K E ET AL:** "A role for the unfolded protein response in optimizing antibody secretion" MOLECULAR IMMUNOLOGY, PERGAMON, GB LNKD- DOI:10.1016/J.MOLIMM.2004.04.023, vol. 41, 5 June 2004 (2004-06-05), pages 919-927, XP002392193 ISSN: 0161-5890

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 396 410 B1

- TIGGES M ET AL: "Xbp1-based engineering of secretory capacity enhances the productivity of Chinese hamster ovary cells" METABOLIC ENGINEERING, ACADEMIC PRESS, US LNKD-DOI:10.1016/J.YMBEN.2006.01.006, vol. 8, no. 3, 1 May 2006 (2006-05-01), pages 264-272, XP024946976 ISSN: 1096-7176 [retrieved on 2006-05-01]

Description

[0001] The present invention relates to a recombinant host cell capable of improved production of a protein of interest. The invention also relates to a method for improving the capability of a cell to produce a protein of interest and a method for producing a protein of interest in such a cell.

Background of the invention

[0002] One of the most important functions of endoplasmic reticulum (ER)-Golgi system is to facilitate post-translational modifications including protein folding. The correct folding of newly-translated proteins is essential for secreted extra-cellular proteins and membrane proteins to ensure that they can function correctly. Protein folding allows a polypeptide to fold into its characteristic and functional three-dimensional structure. Protein folding involves the formation of both non-covalent and covalent bonds. Generally in eukaryotic cells, protein folding is mediated in the rough ER by ER chaperone proteins.

[0003] Protein disulphide isomerase (PDI) is a chaperone protein which catalyzes the formation and isomerisation of disulphide bonds between two cysteine residues in polypeptides. The formation of disulphide bonds is a redox reaction. Proteins are oxidized by PDI when it is in an oxidized state, which produces a disulphide bond in the protein and renders PDI in a reduced state comprising free sulfhydryl groups.

[0004] ER oxidoreductin 1 protein (Ero1) is an essential component of oxidative folding machinery. Ero1 is a flavin adenine dinucleotide (FAD) dependent enzyme which facilitates disulphide bond formation in immunoglobulin subunits by selectively oxidizing PDI (Mezghrani et al., 2001, EMBO Journal, 20(22), 6288-6296). In humans two isoforms have been identified as human Ero1-L α and Ero1-L β .

[0005] US 6,361,964 discloses expression systems that make use of Ero1 to enhance disulphide bond formation and thereby to increase the yield of properly folded recombinant proteins.

[0006] The unfolded protein response (UPR) allows cells to respond to an increased demand on the protein folding capacity of the ER by coordinating the down regulation of protein synthesis with the increased expression of various proteins including ER resident chaperone proteins and folding enzymes which enable protein folding (Gunn et al., 2004, Molecular Immunology, 41, 919-9927). The UPR may also cause enlargement of the ER in order to provide increased capacity for protein folding.

[0007] WO99/07727 describes expression systems that make use of Ero1 to enhance disulfide bond formation and increase the yield of properly folded recombinant proteins. It also disclosed recombinant Ero1 polypeptides, nucleic acids, vectors, and cells for expressing such recombinant polypeptides.

[0008] WO2008/115596 describes methods for increasing secretion of chymosin in filamentous fungi (preferably *T. reesei*) by co-expressing chymosin with the chaperone *bip1* and the foldase Ero1. Ero1 and *bip 1* are regulated by constitutive promoters and chymosin promoter is obtained by the filamentous fungi host (preferably the *cbh1* promoter of *T. reesei*).

[0009] WO2006/067511 describes a method for producing a heterologous protein by: (a) providing a host cell comprising a first recombinant gene encoding a protein comprising the sequence of a first chaperone protein, a second recombinant gene encoding a protein comprising the sequence of a second chaperone protein different from the first chaperone and a third gene, such as a third recombinant gene, encoding the heterologous protein, wherein the first and second chaperones are different; and (b) culturing the host cell in a culture medium to obtain expression of the first, second and third genes.

[0010] X Box Binding Protein 1 (XBP1) is known to be a key regulator of the unfolded protein response. XBP1 is a transcription factor which is involved in B cell differentiation, ER expansion by stimulating activity of enzymes involved in lipid biosynthesis and regulates gene encoding ER resident chaperone proteins involved in the UPR (Lee et al., 2003, Molecular and Cellular Biology, 23(21), 7448-7459). XBP1 is believed to cause enlargement of the ER by up-regulating or activating enzymes including choline cytidyltransferase (CCT). CCT is the rate-limiting enzyme in the CDP-choline pathway for the production of phosphatidylcholine (PtdCho), which is the primary phospholipid of the ER membrane.

[0011] Tigges M et al. "Xbp1-based engineering of secretory capacity enhances the productivity of Chinese hamster ovary cells" (Metabolic Engineering, 2006 vol. 8, no. 3, pages 264 - 272) describes expanding the endoplasmic reticulum and the Golgi apparatus of transgenic CHO-K1 derived cell lines with resulting increase in overall production capacity. Secretory bottlenecks engineered with Xbp-1 showed that Xbp-1 was compatible with a variety of different promoter-product gene configurations.

[0012] The use of XBP1 in methods for protein production wherein a protein of interest is co-expressed with XBP1 are described in WO 2004/111194, WO 2006/028889 and US2005/0250182.

[0013] Accordingly, methods to improve the yield of protein expression systems using a component of the UPR pathway are known. However, there is still a need to provide improved methods for increasing the yield of proteins in expression systems.

Summary of the Invention

[0014] The present invention provides a recombinant host cell capable of improved yield of a protein of interest. The present inventors have demonstrated that an increase of both Ero1 and XBP1 in a cell provides improved means for providing a protein of interest.

[0015] Hence, the present invention provides a recombinant host cell, wherein the cell is modified to comprise an exogenous polynucleotide sequence encoding Ero1 comprising the polypeptide sequence given in SEQ ID NO: 3 or a variant thereof which substantially retains the function of Ero1; and an exogenous polynucleotide sequence encoding XBP1 comprising the polypeptide sequence given in SEQ ID NO:1 or a variant thereof which substantially retains the function of XBP1 and said modified host cell has increased expression levels of Ero1 and XBP1 relative to the expression levels of Ero1 and XBP1 in an unmodified cell.

[0016] The cell provided by the present invention is advantageous because in one embodiment it increases the yield of a protein of interest. In a further embodiment the present method increases the cell's capacity to perform post-translational modifications. The present method may initiate or up-regulate the UPR pathway. Further, the protein of interest expressed by the cell according to the present invention may have substantially the same properties as when the protein is expressed by an unmodified cell.

[0017] The present invention also provides a method comprising modifying a cell to thereby increase the capability of the cell to increase the expression levels of Ero1 and XBP1 relative to the expression levels of Ero1 and XBP1 in an unmodified cell.

[0018] In one aspect of the present invention the method is for expressing a protein of interest. The present inventors have found that the over expression of Ero1 and XBP1 significantly improves the cell's capability to express a protein of interest resulting in higher yields of the protein of interest.

[0019] The present invention also provides an isolated polynucleotide comprising a polynucleotide sequence encoding Ero1 or a variant thereof which substantially retains the function of Ero1; and a polynucleotide sequence encoding XBP1 or a variant thereof which substantially retains the function of XBP1.

Brief Description of the Figures

[0020] In the following drawings specific embodiments of the present invention are described by way of example only, in which:

Figure 1a shows the amino acid sequence of the spliced form of human XBP1 (hXBP1s) (SEQ ID NO:1). The * denotes a stop codon.

Figure 1b shows the nucleic acid sequence of the spliced form of human XBP1 (hXBP1s) (SEQ ID NO:2).

Figure 2a shows the amino acid sequence of human Ero1 α (hEro1 α) (SEQ ID NO:3).

Figure 2b shows the nucleic acid sequence of human Ero1 α (hEro1 α) (SEQ ID NO:4).

Figure 3a shows hEro1 α mRNA expression and Figure 3b shows hXBPs mRNA expression in CHOSXE cell clones (17, 25, 77, 18, 78, 70, 103, 85, 87, 67, 176, 36, 173, 88, 30, 76, 89, 86, 94 and 101), CHOSX and CHOK1E relative to CHOS after a first picking step of CHOSXE cell clones.

Figure 4 shows hEro1 α mRNA and hXBPs mRNA expression after pick 2 of CHOSXE cell clones in CHOSXE cell clones (23, 64, 19, 22, 11, 69, 53, 72, 16, 62, 13, 63, 25, 45, 10, 55, 20, 71, 52, 49 and 57), CHOSX and CHOK1E relative to CHOS after a second picking step of CHOSXE cell clones.

Figure 5 shows the relative increase the expression of antibodies 632 and 497 in cell clones from a CHOS cell line transfected with hEro1 α and hXBP1s (CHOSXE) and a CHOS cell line transfected with hXBP1s (CHOSX) compared to expression of antibodies 632 and 497 in a CHOS cell line.

Figure 6 shows the relative increase the expression of antibodies 146 and 240 from cell clones from a CHOS cell line transfected with hEro1 α and hXBP1s (CHOSXE), a CHOS cell line transfected with hXBP1s (CHOSX) and a CHOK1 cell line transfected with hEro1 α (CHOK1E) compared to expression of antibodies 146 and 240 from a CHOS cell line.

Figure 7 shows a growth curve of cell lines CHOS, CHOSX, CHOSXE, CHOK1 and CHOK1E.

Figure 8 shows the relative increase in expression of antibodies 42, 61 and 164 in CHOSXE and CHOSX compared to the expression of 42, 61 and 164 in CHOS cells.

Figure 9 shows the specific productivity of CHOS, CHOSX and CHOSXE cell lines between day 4 and day 7 for antibodies 42, 61 and 164.

Figure 10 shows the relative heavy chain and kappa light chain mRNA expression for antibodies 42, 61 and 164 expressed in CHOSX and CHOSXE cell lines compared to CHOS cell line.

Figure 11 shows the % aggregation of antibodies 42, 61 and 164 expressed in CHOK1, CHOS, CHOSX and CHOSXE.

Figure 12a shows an SDS PAGE of antibody 42 expressed in CHOS, CHOSX CHOSXE and CHOK1; Figure 12b

shows an SDS PAGE of antibody 61 expressed in CHOS, CHOSX CHOSXE and CHOK1; and Figure 12c shows an SDS PAGE of antibody 164 expressed in CHOS, CHOSX CHOSXE and CHOK1.

Figure 13 shows the results from a thermofluor assay of antibodies 42, 61 and 164 expressed in CHOS and CHOSXE.

Figure 14 shows the glycosylation profiles of antibodies 42, 61 and 164 expressed in CHOS and CHOSXE.

Figure 15 shows the results from an antigen binding assay of 164 expressed in CHOS and CHOSXE.

Detailed Description of the Invention

[0021] The present invention provides a recombinant host cell which has improved capacity to produce a protein of interest due to modification of the cell to increase Ero1 and XBP1 expression. The present inventors have found that an increase of Ero1 and XBP1 in a host cell significantly improves protein yield compared to an unmodified cell. Preferably the cell according to the present invention has a specific productivity of a protein of interest of 80% or more, 85% or more, 90% or more, 100% or more, 150% or more, 200% or more, 300% or more, 400% or more, 500% or more, 600% or more, 700% or more or 800% or more relative to control cells which have not been modified to increase Ero1 and XBP1. More preferably the cell according to the present invention has a specific productivity of a protein of interest of from 100% to 1000%, more preferably 200% to 1000%, still more preferably 500% to 1000% relative to control cells which have not been modified to increase Ero1 and XBP1.

[0022] Moreover, the present inventors have found that the cell according to the present invention has improved protein yield compared to a cell over expressing either Ero1 or XBP1 with the protein of interest.

[0023] In one embodiment the cell according to the present invention has a specific productivity of a protein of interest greater than the combined cellular productivity of a protein of interest from a cell modified to increase the expression of Ero1 but not XBP1 and a cell modified to increase XBP1 but not Ero1. Preferably the cell according to the present invention has a specific productivity of a protein of interest of 5% or more, 6% or more, 10% or more, 20% or more, 30% or more, 40% or more, 50% or more, 60% or more, 70% or more 80% or more, 90% or more, 100% or more, 110% or more, 120% or more, 130% or more, 140% or more, 150% or more, more preferably 5% to 150%, 6% to 130%, 10% to 130% or 50% to 130% relative to the combined cellular productivity of a protein of interest from a cell modified to increase the expression of Ero1 but not XBP1 and a cell modified to increase XBP1 but not Ero1.

[0024] Preferably the cell according to the present invention has a specific productivity of a protein of interest of 2 or more $\mu\text{g}/1 \times 10^6 \text{cells/day}$, preferably 3 or more $\mu\text{g}/1 \times 10^6 \text{cells/day}$, more preferably more than 3 $\mu\text{g}/1 \times 10^6 \text{cells/day}$, still more preferably 3.2 or more $\mu\text{g}/1 \times 10^6 \text{cells/day}$, more preferably 3.2 to 6.5 $\mu\text{g}/1 \times 10^6 \text{cells/day}$.

[0025] The skilled person would easily be able to test a candidate cell clone to see if it has the desired yield of a protein of interest using methods well known in the art, such as ELISA.

[0026] In a further embodiment the co-expression of both Ero1 and XBP1 provides improved yield of correctly folded proteins from the cell relative to unmodified cells. The skilled person would easily be able to test secreted protein to see if the protein is correctly folded using methods well known in the art, such as protein G HPLC, circular dichroism, NMR and X-Ray crystallography.

[0027] Without wishing to be bound by theory it is believed that the improved protein expression is due to the increased capacity of the cell to fold proteins. Specifically, increase of Ero1 expression increases the cell's capacity to form disulphide bonds in protein in the ER. In addition, the increase of XBP1 expression causes up-regulation of ER chaperone protein expression and may enlarge the size of the ER. The cell provided by the present invention may also provide an increased yield of protein relative to unmodified cells due to the increased capacity of the cell to fold all proteins expressed by the cell, which thereby increases all cellular pathways including transcription, translation, protein folding and secretory pathways. Further, due to the increase of Ero1 and XBP1 increasing the cell's capacity to process newly translated proteins, any feedback control of mRNA transcription and/or protein translation may cause an increase in protein transcription and/or translation.

[0028] In a further embodiment the co-expression of both Ero1 and XBP1 in the cell of the invention provides improved cell growth and/or stability and/or reproduction relative to unmodified cells. Preferably the cells provided by the present invention have increased cell density after the same period of culture of 30% or more, 50% or more, 60% or more, 70% or more, 80% or more, 90% or more, 100% or more, 130% or more, 150% or more, 170% or more, or 190% or more compared to the cell density of a culture of control cells which have not been modified to up-increase Ero1 and XBP1.

[0029] The skilled person would easily be able to select cells having improved cell growth and/or stability and/or reproduction by, for example, measuring the cell density and/or cell viability of a cell culture after a fixed culture period. Suitable methods known the art include the CEDEX (Innovatis) automated cell counting system based on the well-established Trypan Blue exclusion method for determining cell viability. Sample handling, staining, cell counting and graphical analysis of the results are performed automatically by the CEDEX system.

[0030] Without wishing to be bound by theory it is believed that the improved cell growth and/or stability are due to the increased capacity of the cell to process all proteins which require post-translational modifications in the ER, which thereby increases cellular pathways. Accordingly, the production of correctly folded proteins necessary for the cell's

growth and reproduction may be increased thereby improving the cellular pathways regulating growth and/or stability and/or reproduction.

[0031] These findings are unexpected, particularly because XBP1 and Ero1 are not linked in a UPR pathway. The UPR is extremely complex and involves numerous different pathways. Whilst co-expression of either XBP1 or Ero1 with additional components or modulators of the same UPR pathway may be expected to improve protein expression, it is surprising that co-expression of two unconnected proteins would provide a significantly improved protein expression system.

[0032] The present invention will now be described in more detail.

[0033] The terms "protein" and "polypeptide" are used interchangeably herein, unless the context indicates otherwise. "Peptide" is intended to refer to 10 or less amino acids.

[0034] The terms "polynucleotide" includes a gene, DNA, cDNA, RNA, mRNA etc unless the context indicates otherwise.

[0035] As used herein, the term "comprising" in context of the present specification should be interpreted as "including".

[0036] In one aspect of the present invention there is provided a recombinant host cell modified to comprise an exogenous polynucleotide sequence encoding Ero1 comprising the polypeptide sequence given in SEQ ID NO: 3 or a variant thereof which substantially retains the function of Ero1; and an exogenous polynucleotide sequence encoding XBP1 comprising the polypeptide sequence given in SEQ ID NO:1 or a variant thereof which substantially retains the function of XBP1 and said modified host cell has increased expression levels of Ero1 and XBP1 relative to the expression levels of Ero1 and XBP1 in an unmodified cell.

[0037] The unmodified cell or control cell in the context of the present invention means a cell of the same type as the host cell wherein the cell has not been modified to increase/up-regulate/over-express the expression levels of Ero1 and XBP1, for example the unmodified cell may be derived from a population of host cells before modification to increase/up-regulate/over-express the expression levels of Ero1 and XBP1.

[0038] In one embodiment the cell comprises an exogenous recombinant polynucleotide sequence encoding Ero1 or a variant thereof which substantially retains the function of Ero1; and an exogenous recombinant polynucleotide encoding XBP1 or a variant thereof which substantially retains the function of XBP1. In this embodiment the cell may comprise a polynucleotide encoding both Ero1 and XBP1 and/or the cell may comprise separate polynucleotides encoding Ero1 and XBP1.

[0039] As used herein, "the polynucleotide", "the polynucleotide encoding Ero1", "the polynucleotide encoding XBP1" and "the polynucleotide encoding Ero1 and XBP1" are intended to refer to all aspects and embodiments of the present invention wherein Ero1 and XBP1 may be encoded by the same and/or separate polynucleotides, unless stated otherwise.

[0040] Accordingly, the cell according to the present invention may comprise an exogenous Ero1 and XBP1 polynucleotide comprising both a polynucleotide sequence encoding Ero1 and a polynucleotide sequence encoding XBP1. The cell according to the present invention may also comprise such a polynucleotide in the form of an expression cassette or a vector.

[0041] Alternatively or additionally, the cell according to the present invention comprises an exogenous Ero1 polynucleotide comprising the polynucleotide sequence encoding Ero1 and a separate exogenous XBP1 polynucleotide comprising the polynucleotide sequence encoding XBP1. Accordingly, the cell according to the present invention may comprise an Ero1 expression cassette or vector comprising the Ero1 polynucleotide and a separate XBP1 expression cassette or vector comprising the XBP1 polynucleotide.

[0042] In a further embodiment the increased Ero1 and XBP1 expression is from modulation of endogenous polynucleotides encoding Ero1 and XBP1 in the cell according to the present invention. In this embodiment the cell is modified to increase transcription and translation of the endogenous genes of Ero1 and XBP1.

[0043] The cell according to the present invention may further comprise a polynucleotide sequence encoding a protein of interest. The polynucleotide sequence encoding the protein of interest may be exogenous or endogenous. The polynucleotide sequence encoding the protein of interest may be integrated into the host's chromosome or may be non-integrated in an episome.

[0044] In the embodiment wherein the polynucleotide sequence encoding the protein of interest is exogenous and the cell comprises one or more exogenous polynucleotides encoding Ero1 and XBP1, the polynucleotide sequence encoding the protein of interest may be part of one or more of the Ero1 and/or XBP1 encoding exogenous polynucleotides. Accordingly, the polynucleotide sequence encoding a protein of interest may be in the same polynucleotide sequence as both XBP1 and Ero1. Alternatively or additionally the polynucleotide sequence encoding a protein of interest may be in the same polynucleotide sequence as either the separate Ero1 polynucleotide sequence and/or the separate XBP1 polynucleotide sequence. Alternatively or additionally, the cell may further comprise a separate polynucleotide, an expression cassette or a vector comprising the polynucleotide sequence encoding the protein of interest.

[0045] Suitable cells for employing in the invention include eukaryotic cells, for example plant cells, insect cells, yeast cells, animal cells such as mammalian cells, in particular CHO cells, myeloma cells, viro cells, MRC5 Cells, HEK cells, NSO cells, SP2 cells and the like.

[0046] CHO cells have been found to be particularly useful for mammalian expression because the proteins expressed in CHO cells have glycoforms that are generally compatible and bioactive in humans. Accordingly, in one aspect the invention employs a mammalian cell such as a CHO cell, for example a CHOS cell (Invitrogen Cat. No. 11619-012, Deaven, L.L. et al, 1973, Chromasoma 41, 129, D'Anna, J.A. et al, 1996, Methods in Cell Science 18, 115, D'Anna, J.A. et al, 1997, Radiation Research 148, 260) or CHOK1 cell (Puck, T. et al. 1967, Genetics of Somatic Mammalian Cells IV Properties of Chinese Hamster Cell Mutants With Respect To The Requirement For Proline; Genetics; 55; 513-524; March 1967), or a derivative therefrom.

[0047] In one embodiment the cell provided by the present invention is the modified CHOS cell strain Depositor Deposit Name: CHOSXE (Depositor Identification in Full: CHOS.Xbp1.Ero1a), which was deposited on 10th February 2010 by UCB Celltech, the UK branch of UCB Pharma S.A., at the European Collection of Cell Cultures (ECACC), HPA, United Kingdom, under HPA Culture Collections Reference Number: Q8515 and Accession number: 10021001 in accordance with The Budapest Treaty.

[0048] As used herein, "Ero1" means a polypeptide having the activity of facilitating disulphide bond formation by oxidizing PDI. Ero1 polypeptide is formerly known as Sec81.

[0049] Any suitable form of Ero1 from any suitable source may be used in the present invention including Ero1 α and Ero1 β . Typically human Ero1-L α and/or Ero1-L β may be used in the present invention.

[0050] In one embodiment, the polynucleotide encoding Ero1 used in the present invention encodes a variant polypeptide of the endogenous form of Ero1 which substantially retains the activity of oxidizing PDI.

[0051] A variant polypeptide in the context of the present specification is intended to refer to a sequence that has one or more amino acid substitutions, deletions or insertions compared to the endogenous polypeptide but retains all or substantially all of the function such as 80% or more, in particular 90% or more, for example 95% or more or 100% of the activity of the endogenous polypeptide.

[0052] The polynucleotide sequence encoding Ero1 used in the present invention encodes an Ero1 polypeptide sequence comprising the polypeptide sequence shown in SEQ ID NO: 3. Amino acids 1 to 23 of SEQ ID NO:3 encode a signal peptide. Accordingly the polynucleotide sequence encoding Ero1 used in the present invention may or may not comprise the signal peptide and therefore may comprise amino acids 1 to 468 or amino acids 24 to 468. It will be appreciated that one or more amino acid substitutions, insertions or deletions may be made to SEQ ID NO: 3 without significantly altering the activity of Ero1. The effect of any amino acid substitutions, insertions or deletions can be readily tested by one skilled in the art by any suitable method. For example, an anti-Ero1 antibody may be used to determine Ero1 presence and the redox environment of the cell may be tested to determine Ero1 activity. Accordingly, in one embodiment, the polynucleotide sequence encoding Ero1 of the present invention encodes a polypeptide sequence having at least 60%, 70%, 80%, 90%, 95% or 98% identity or similarity to the sequence given in SEQ ID NO: 3.

[0053] "Identity", as used herein, indicates that at any particular position in the aligned sequences, the amino acid residue is identical between the sequences. "Similarity", as used herein, indicates that, at any particular position in the aligned sequences, the amino acid residue is of a similar type between the sequences. For example, leucine may be substituted for isoleucine or valine. Other amino acids which can often be substituted for one another include but are not limited to:

- phenylalanine, tyrosine and tryptophan (amino acids having aromatic side chains);
- lysine, arginine and histidine (amino acids having basic side chains);
- aspartate and glutamate (amino acids having acidic side chains);
- asparagine and glutamine (amino acids having amide side chains); and
- cysteine and methionine (amino acids having sulphur-containing side chains).

[0054] Degrees of identity and similarity can be readily calculated (Computational Molecular Biology, Lesk, A.M., ed., Oxford University Press, New York, 1988; Biocomputing. Informatics and Genome Projects, Smith, D.W., ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part 1, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991).

[0055] It will be appreciated that any suitable polynucleotide sequence encoding an Ero1 polypeptide may be used. In one embodiment the polynucleotide sequence encoding Ero1 comprising the polynucleotide sequence shown in SEQ ID NO:4. The polynucleotide sequence shown in SEQ ID NO:4 may have one or more nucleotide substitutions, insertions or deletions without significantly altering the activity of Ero1. Accordingly, in one embodiment, the polynucleotide sequence encoding Ero1 comprises a sequence having at least 60%, 70%, 80%, 90%, 95% or 98% identity or similarity to the sequence given in SEQ ID NO: 4. In a further embodiment, the invention encompasses the use of polynucleotides that are complementary to, antisense to or hybridize under stringent conditions to the polynucleotide described herein.

[0056] The Ero1 employed in the present invention may be derived from any suitable source, for example human, mouse, hamster or yeast.

[0057] As used herein, "XBP1" means a polypeptide having transcription activation activity for one or more UPR genes including ER chaperone proteins.

[0058] Two isoforms of XBP-1 exist resulting from alternative splicing events. The XBP-1 gene is transcribed into a mRNA which encodes an unspliced version of XBP-1 and a shorter spliced mRNA is also generated which lacks exons. XBP-1 mRNA is spliced in response to ER stress, such as the accumulation of unfolded protein in the ER. It has been shown that only the spliced form of XBP-1 can efficiently activate the UPR pathway (Yoshida et al., 2001, Cell, 107, 881-891). Accordingly, the polynucleotide according to the present invention preferably encodes the spliced form of XBP1.

[0059] In one embodiment, the polynucleotide encoding XBP1 used in the present invention encodes a variant polypeptide of the endogenous form of XBP1 which substantially retains the transactivator activity of XBP1.

[0060] The polynucleotide sequence encoding XBP1 used in the present invention encodes a polypeptide sequence comprising the polypeptide sequence shown in SEQ ID NO: 1. It will be appreciated that one or more amino acid substitutions, insertions or deletions may be made to SEQ ID NO: 1 without significantly altering the activity of XBP1. The effect of any amino acid substitutions, insertions or deletions can be readily tested by one skilled in the art. For example, a BODIPY staining method may be used to measure the size of the ER because XBP1 activity increases the size of the ER. The activity of choline cytidylyltransferase alpha (CCTalpha) may also be used to determine XBP1 activity because the activity of CCT alpha is increased by XBP1 over-expression.

[0061] In one embodiment, the polynucleotide sequence encoding XBP1 of the present invention encodes a polypeptide sequence having at least 60%, 70%, 80%, 90%, 95% or 98% identity or similarity to the sequence given in SEQ ID NO: 1.

[0062] It will be appreciated that any suitable polynucleotide sequence encoding an XBP1 polypeptide may be used. In one embodiment the polynucleotide sequence encoding XBP1 comprises the polynucleotide sequence shown in SEQ ID NO:2, wherein SEQ ID NO:2 is the spliced form of XBP1. The polynucleotide sequence shown in SEQ ID NO:2 may have one or more nucleotide substitutions, insertions or deletions without significantly altering the activity of XBP1. Accordingly, in one embodiment, the polynucleotide sequence encoding XBP1 comprises a sequence having at least 60%, 70%, 80%, 90%, 95% or 98% identity or similarity to the sequence given in SEQ ID NO: 2. In a further embodiment, the invention encompasses the use of polynucleotides that are complementary to, antisense to or hybridize under stringent conditions to the polynucleotide described herein.

[0063] The XBP1 employed in the present invention may be derived from any suitable source, for example human, mouse, hamster or yeast.

[0064] In one embodiment the modified cell according to the present invention expresses a protein of interest. "Protein of interest" in the context of the present specification is intended to refer to polypeptide for expression, usually a recombinant polypeptide. However, the protein of interest may be an endogenous protein expressed from an endogenous gene in the host cell.

[0065] As used herein, a "recombinant polypeptide" refers to a protein that is constructed or produced using recombinant DNA technology. The protein of interest may be an exogenous sequence identical to the endogenous protein or a mutated version thereof, for example with attenuated biological activity, or fragment thereof, expressed from an exogenous vector. Alternatively, the protein of interest may be a heterologous protein, not normally expressed by the host cell.

[0066] The protein of interest may be any suitable protein including therapeutic, prophylactic or diagnostic protein.

[0067] The protein of interest expressed by the cells according to the invention may, for example be an immunogenic protein, a fusion protein comprising two heterologous proteins or an antibody. Antibodies for use as the protein of interest include monoclonal, multi-valent, multi-specific, humanized, fully human or chimeric antibodies. The antibody may be a complete antibody molecule having full length heavy and light chains or a fragment thereof, e.g. VH, VL, VHH, Fab, modified Fab, Fab', F(ab')₂, Fv or scFv fragment.

[0068] After expression antibody fragments may be further processed, for example by conjugation to another entity or for example the antibody fragments may be PEGylated to generate a product with the required properties, for example similar to the whole antibodies, if required.

[0069] The cell and one or more polynucleotides employed in the present invention may also comprise further polynucleotide sequences encoding one or more further proteins of interest.

[0070] The polynucleotides employed in the present invention may be incorporated into the host cell using any suitable means known in the art. Typically, each polynucleotide is incorporated as part of an expression cassette which may be integrated into the chromosome or genome of the host cell or introduced via a non-integrated expression vector.

[0071] The expression cassette employed in the present invention typically comprises one or more protein coding sequences and one or more regulatory expression sequences. The one or more regulatory expression sequences may include a promoter. The one or more regulatory expression sequences may also include a 3' untranslated region such as a polyadenylation sequence or other termination sequences. In one embodiment, each expression cassette comprises a promoter, a protein coding sequence and a polyadenylation sequence. Suitable promoters are discussed in more detail below.

[0072] In the embodiment wherein the expression cassette comprises two or more polynucleotide sequences encoding proteins selected from Ero1, XBP1 and the protein of interest, each coding sequence is operatively linked to one or more

suitable regulatory expression sequences to allow expression of each protein.

[0073] The polynucleotide sequence encoding a protein of interest may be in the same vector as both XBP1 and Ero1. Alternatively or additionally the polynucleotide sequence encoding a protein of interest may be in the same vector as the Ero1 polynucleotide sequence. Alternatively or additionally the polynucleotide sequence encoding a protein of interest may be in the same vector as the XBP1 polynucleotide sequence. Alternatively or additionally, the cell may further comprise a separate vector comprising the polynucleotide sequence encoding the protein of interest.

[0074] The vector for use in the present invention may be produced by inserting an expression cassette as defined above into a suitable vector. Alternatively, the regulatory expression sequences for directing expression of each polynucleotide sequence encoding a protein may be contained in the vector and thus only the encoding region of the one or more polynucleotides may be required to complete the vector.

[0075] The promoters employed in the present invention can be linked to the relevant polynucleotide directly or alternatively be located in an appropriate position, for example in a vector such that when the relevant polypeptide is inserted the relevant promoter can act on the same. One promoter may be employed for all the encoded sequences but greater levels of expression are generally obtained when each polypeptide encoded has a specific promoter.

[0076] Therefore in one embodiment one, two, three or more promoters are employed.

[0077] In one embodiment one or more promoters are located in the polynucleotide employed in the invention.

[0078] In one embodiment the promoter is located before the encoding portion of the polynucleotide on which it acts, for example a relevant promoter before each encoding portion of polynucleotide. "Before" as used herein is intended to imply that the promoter is located at the 5 prime end in relation to the encoding polynucleotide portion.

[0079] The promoters employed in the present invention may be the same or different for each polynucleotide. The promoters may be endogenous or exogenous to the host cells. Suitable promoters include CMV such as hCMV (for example suitable as a promoter when the polypeptide is an antibody), viral LTR promoters and SV40 promoter.

[0080] One or more promoters employed may be inducible promoters.

[0081] In one embodiment, the polynucleotide employed in the present invention comprises a polyadenylation signal sequence, for example, associated with each polynucleotide sequence encoding a protein selected from Ero1, XBP1 and the protein of interest as appropriate, such as at the end of (for example at the C-terminal (3 prime) end of) each encoding polynucleotide. Expression vectors, in particular, may require signal sequences that encode for a polyadenylation tail. The polyadenylation signal sequence causes a polyadenylation tail to be added at the end of the transcribed pre-mRNA that may protect the mRNA from exonucleases thereby stabilizing mRNA and may terminate transcription.

[0082] Examples of polyadenylation tails include SV40poly A, BgH polyA and synthetic polyA tail, in particular SV40 poly A.

[0083] In one embodiment the polynucleotide employed in the present invention comprises one or more introns. In one embodiment the polynucleotide sequence comprises an intron before the start codon, i.e. at the 5 prime end. In one embodiment the polynucleotide sequence comprises an intron after the stop codon, i.e. at the 3 prime end. In one embodiment the polynucleotide sequence comprises 1, 2 or 3 introns. In one embodiment the polynucleotide sequence comprises an intron before the start codon and after the stop codon. The intron may be derived from any gene, particularly a gene from which the encoded sequence is derived.

[0084] In one or more embodiments the polynucleotide employed in the present invention comprises a Kozak sequence associated with each polynucleotide sequence encoding a protein selected from Ero1, XBP1 and the protein of interest as appropriate. Whilst not wishing to be bound by theory it is thought that the Kozak sequence is an optimal ribosome binding site.

[0085] Embodiments of the invention described herein with reference to the polynucleotide apply equally to alternative embodiments of the invention, for example vectors, expression cassettes and/or host cells comprising the components employed therein, as far as the relevant aspect can be applied to same.

[0086] The present invention also provides a method comprising modifying a cell to increase the capability of the cell to increase the expression levels of Ero1 and XBP1 relative to the expression levels of Ero1 and XBP1 in an unmodified cell wherein the method comprises transfecting the cell with one or more polynucleotides, as defined herein.

[0087] The increase of Ero1 and XBP1 may be performed using any suitable means known in the art. For example, the cell may be transfected with one or more polynucleotides, one or more expression cassettes and/or one or more vectors encoding:

an exogenous polynucleotide sequence encoding Ero1 or a variant thereof which substantially retains the function of Ero1; and

an exogenous polynucleotide sequence encoding XBP1 or a variant thereof which substantially retains the function of **XBP1**.

[0088] In this embodiment the one or more polynucleotides, one or more expression cassettes and/or one or more vectors are as described above. Accordingly, the method according to the present invention may employ the polynucle-

otide according to the present invention wherein the polynucleotide comprises a polynucleotide sequence comprising Ero1 and a polynucleotide sequence comprising XBP1. Additionally or alternatively, the method according to the present invention employs separate polynucleotides encoding Ero1 and XBP1, as described above.

5 [0089] The one or more polynucleotides employed in the present invention, preferably in the form of one or more expression cassettes or one or more vectors, can be incorporated into a cell in various ways. In one embodiment the one or more polynucleotides are integrated into a chromosome or the genome of the cell to allow stable expression. In a further embodiment of the invention the cell is transiently transfected using, for example a non-integrating vector.

10 [0090] In the embodiment wherein the Ero1 polynucleotide sequence and XBP1 polynucleotide sequence are separate, each polynucleotide sequence, preferably in the form of an expression cassette or vector, may be introduced into a cell simultaneously or sequentially.

15 [0091] The one or more polynucleotide sequences can be introduced into a cell using standard techniques, for example employing electroporation, or lipid based methods (lipotransfection), anionic transfection, cationic transfection such as employing calcium phosphate, heat shock, magnetofection, transfection agents such as lipofectamine, dendrimers, DEAE-dextran transfection, transduction employing a virus. In one embodiment cationic transfection such as employing calcium phosphate is employed.

20 [0092] The method according to the present invention may also employ a selection system to facilitate selection of stable cells which have been successfully transfected with the one or more polynucleotides. The selection system typically employs co-transfection of a polynucleotide sequence encoding a selection marker. In one embodiment, each polynucleotide transfected into the cell further comprises a polynucleotide sequence encoding one or more selection markers. Accordingly, the transfection of the one or more polynucleotides of the present invention and the one or more polynucleotides encoding the marker occurs together and the selection system can be employed to select those cells which produce the desired proteins.

25 [0093] Cells able to express the one or more markers are able to survive/grow/multiply under certain artificially imposed conditions, for example the addition of a toxin or antibiotic, because of the properties endowed by the polypeptide/gene or polypeptide component of the selection system incorporated therein (e.g. antibiotic resistance). Those cells that cannot express the one or more markers are not able to survive/grow/multiply in the artificially imposed conditions. The artificially imposed conditions can be chosen to be more or less vigorous, as required.

30 [0094] Any suitable selection system may be employed in the present invention. Typically the selection system may be based on including in the vector one or more genes that provides resistance to a known antibiotic, for example a kanamycin or ampicillin resistance gene. Cells that grow in the presence of a relevant antibiotic can be selected as they express both the gene that gives resistance to the antibiotic and the desired protein. Other suitable selection systems include the use of geneticin, also known as G418, which is a toxin that can be neutralized by the product of a neomycin resistant gene; the use of the enzyme dihydrofolate reductase (DHFR), which is essential for the *de novo* synthesis of glycine, purine and thymidine, optionally in combination with an inhibitor of DHFR namely, methotrexate; and the use of glutamine synthetase (GS), which catalyses the formation of glutamine from glutamate and ammonia, optionally in combination with an inhibitor of GS, such as methionine sulphoximine (MSX). The Zeocin™ selection system may also be employed in the present invention. Zeocin™ is an antibiotic from *Streptomyces* and the selection system employs the use of a Zeocin™ resistant protein.

35 [0095] In one embodiment, the method according to the present invention further comprises the step of culturing the transfected cell in a medium to thereby express increased levels of Ero1 polypeptide and XBP1 polypeptide and optionally any selection marker.

40 [0096] In this embodiment the method according to the present invention may further comprise the following steps:

- 45
- a. selecting one or more modified cell clones;
 - b. measuring the quantity of Ero1 mRNA and/or protein in the selected one or more cell clones; and
 - c. measuring the quantity of XBP1 mRNA and/or protein in the selected one or more clones.

50 [0097] Steps b and c may be carried out simultaneously or sequentially in any order. The skilled person would know from their common general knowledge suitable method for measuring the mRNA and/or protein levels of Ero1 or XBP1 in modified cell clones. Techniques for measuring the increase of Ero1 and XBP1 expression include ELISA for protein quantification and Taqman quantitative PCR analysis and Northern Blot analysis for mRNA quantification.

[0098] The method further comprises the steps of:

- 55
- d. comparing the quantity of Ero1 mRNA and/or protein and XBP1 mRNA and/or protein to the quantity of Ero1 mRNA and/or protein and XBP1 mRNA and/or protein in an unmodified cell clone; and
 - e. selecting one or more modified cell clones having a higher quantity of Ero1 mRNA and/or protein and XBP1 mRNA and/or protein compared to the unmodified cell clone.

[0099] In step d the quantity of Ero1 mRNA and/or protein and XBP1 mRNA and/or protein is compared to the quantity of Ero1 mRNA and/or protein and XBP1 mRNA and/or protein in an unmodified cell clone. Alternatively the quantity of Ero1 mRNA and/or protein and XBP1 mRNA and/or protein may be compared to the quantity of Ero1 mRNA and/or protein and XBP1 mRNA and/or protein in one or more other modified cell clones. In this embodiment, step e may comprise selection of the modified cell clones showing a higher quantity of Ero1 mRNA and/or protein and XBP1 mRNA and/or protein compared to other modified cell clones.

[0100] In step e, any suitable number of modified cell clones may be selected which have higher quantity of Ero1 mRNA and/or protein and XBP1 mRNA and/or protein compared to the unmodified cell clone. Typically one or more cell clones having the highest quantity of Ero1 mRNA and/or protein and XBP1 mRNA and/or protein are selected. The one or more cell clones which are selected in step e may then be selected for further growth and use for expressing a protein of interest. The method may comprise repeating steps b, c, d and e one or more times.

[0101] The skilled person would easily be able to identify modified cell clones having a higher quantity of Ero1 mRNA and XBP1 mRNA compared to the unmodified cell clone, such as a CHOS cell. Examples of suitable relative quantity of Ero1 mRNA and XBP1 mRNA compared to a CHOS cell which has no detectable Ero1 mRNA and XBP1 mRNA (which is counted as 1 for the purpose of calculating relative amount), may be for Ero1 mRNA: 5000 or more fold increase, 5000 to 500000 fold increase, 10000 to 400000 fold increase, 30000 to 400000 fold increase, 100000 to 400000 fold increase; and for XBP1 mRNA: 150 or more fold increase, 150 to 150000 fold increase, 300 to 110000 fold increase, 5000 to 110000 fold increase.

[0102] The present invention also provides one or more modified cell clones as produced by the method described above. The present inventors have found that the modified cell clones produced by the above method are capable of expressing a protein of interest at a higher yield compared to an unmodified cell clone.

[0103] In one embodiment the method further comprises transfecting the host cell with a polynucleotide sequence encoding a protein of interest and expressing the protein of interest. The method may also include a further step of measuring the quantity of expression of the protein of interest and selecting one or more cell clones having high expression levels of the protein of interest. Accordingly, the present invention also provides a method of producing a recombinant protein of interest comprising expressing the recombinant protein of interest in a modified host cell in which the expression levels of XBP1 and Ero1 are increased. XBP1 and Ero1 are described above.

[0104] In the embodiment wherein the cell is also transfected with a polynucleotide sequence encoding a protein of interest which is a separate polynucleotide to the one or more Ero1 and XBP1 polynucleotides, the polynucleotide sequence encoding a protein of interest may be introduced into the host cell simultaneously with the one or more Ero1 and XBP1 polynucleotides, wherein the Ero1 and XBP1 polynucleotide sequences may be in the same or separate polynucleotides. Alternatively, the polynucleotide sequence encoding a protein of interest may be introduced into the host cell before or after the one or more Ero1 and XBP1 polynucleotides are introduced into the host cell. In the embodiment wherein the Ero1 and XBP1 polynucleotide sequences are separate polynucleotides the polynucleotide sequence encoding a protein of interest may be introduced into the host cell before or after one or both of the Ero1 and XBP1 polynucleotides.

[0105] In a preferred embodiment the polynucleotide sequence encoding a protein of interest is introduced into the host cell after the one or more Ero1 and XBP1 polynucleotides have been introduced into the host cell and, more preferably the polynucleotide sequence encoding a protein of interest is introduced into the host cell after the modified cells have been selected which show increased Ero1 and XBP1 expression.

[0106] An inducible expression system may be used in the present invention to express the Ero1 protein and/or the XBP1 protein and/or the protein of interest. Suitable inducible expression systems are well known in the art.

[0107] Any suitable medium may be used to culture the transfected cell. The medium may be adapted for a specific selection system, for example the medium may comprise an antibiotic, to allow only those cells which have been successfully transfected to grow in the medium. The method according to the present invention may also comprise a step of selecting those cells in the medium which have been successfully transfected, such as by selecting cells which are able to grow in the medium.

[0108] The cells obtained from the medium may be subjected to further screening and/or purification as required. In the embodiment wherein the cell comprises a polynucleotide sequence encoding a protein of interest and the protein of interest is expressed, the method may further comprise one or more steps to extract and purify the protein of interest as required.

[0109] One or more method steps described herein may be performed in combination in a suitable container such as a bioreactor.

[0110] The present invention also extends to cell cultures that are transfected or transduced with one or more polynucleotides, as described herein.

[0111] The present inventors have demonstrated that the co-expression of both Ero1 and XBP1 in a cell provides improved means for expressing a protein of interest.

[0112] As discussed above, with respect to the cell according to the present invention, in a preferred embodiment the

method according to the present invention increases the yield of expressed protein of interest from the cell compared to the yield of expressed protein of interest from an unmodified cell which has not been modified to increase either Ero1 or XBP1, more preferably compared to the yield of expressed protein of interest from a cell which has been modified to increase either Ero1 or XBP1 and still more preferably compared to the combined yield of expressed protein of interest from a cell modified to increase the expression of Ero1 but not XBP1 and a cell modified to increase XBP1 but not Ero1.

[0113] Further, as discussed previously, the method according to the present invention preferably provides a cell having increased cell growth and/or stability and/or reproduction after the same period of culture relative to unmodified cells which have not been modified to increase Ero1 and XBP1.

[0114] The present invention also provides an isolated polynucleotide comprising a polynucleotide sequence encoding Ero1 or a variant thereof which substantially retains the function of Ero1; and a polynucleotide sequence encoding XBP1 or a variant thereof which substantially retains the function of XBP1. Suitable polynucleotide sequences including preferred sequences are described above with respect to the cell according to the present invention, wherein both Ero1 and XBP1 are part of the same polynucleotide sequence.

[0115] The present invention also provides an expression cassette and a vector comprising the polynucleotide according to the present invention.

[0116] The invention also extends to an expression system comprising a recombinant polynucleotide sequence encoding Ero1 or a variant thereof which substantially retains the function of Ero1; a recombinant polynucleotide sequence encoding XBP1 or a variant thereof which substantially retains the function of XBP1; and a suitable medium.

[0117] The expression system may comprise a polynucleotide comprising both Ero1 and XBP1 or may comprise separate polynucleotides comprising Ero1 and XBP1. The one or more polynucleotides are preferably comprised within one or more expression cassettes and/or one or more vectors as described previously. The expression system may comprise a cell suitable for transfecting with the one or more polynucleotide. Thus the invention provides a composition comprising a polynucleotide according to the invention and a cell complementary thereto, for example in admixture and/or wherein the relevant polynucleotide is located within the cell. In one embodiment the expression system comprises a cell comprising the one or more polynucleotides as defined above.

[0118] The expression system may further comprise one or more polynucleotides encoding different proteins of interest.

[0119] The invention also extends to use of a recombinant polynucleotide sequence encoding Ero1 and a recombinant polynucleotide sequence encoding XBP1 for expressing a protein of interest.

[0120] In a further aspect the invention provides use of a recombinant polynucleotide sequence encoding Ero1 and a recombinant polynucleotide sequence encoding XBP1 in one or more expression cassettes, one or more vectors or one or more cells as described above for expressing a protein of interest.

[0121] The present invention also provides a polynucleotide as defined above, an expression cassette as defined above, a vector as defined above, a cell as defined above or an expression system as defined above for use as a medicament.

[0122] The present invention also encompasses a pharmaceutical composition comprising a polynucleotide as defined above, an expression cassette as defined above, a vector as defined above, a cell as defined above or an expression system as defined above.

[0123] In a further embodiment, wherein a polynucleotide sequence encoding a protein of interest is employed in the present invention, the protein of interest may be a therapeutic or prophylactic protein suitable for the treatment of a human or non-human animal in need thereof.

[0124] One or more embodiments of the invention described herein may be combined unless they are technically incompatible.

[0125] Specific embodiments of the invention are described herein comprising certain entities. The invention also extends to separate embodiments that consist or consist essentially of said elements.

[0126] The invention will now be illustrated by reference to the following examples.

Examples

DNA manipulations and general methods

[0127] CHOS cells (Invitrogen) and CHOK1 cells (ATCC) were used for transformation and routine culture growth. DNA restriction and modification enzymes were obtained from New England Biolabs.

[0128] The spliced form of human XBP1 (SEQ ID NO:2) and Human Erola (SEQ ID NO:4) were used.

[0129] Nucleotide sequences for Erola and XBP1 were chemically synthesized by Entelechon.

[0130] The pCDNA3.1(+)-vectors comprising the gene of interest, were transfected into the host cells using electroporation (for CHOSX and CHOK1E cells) or lipofectamine (for CHOSXE cells).

[0131] In example 2 and 3 the mammalian expression vectors used contained both sequences encoding the heavy and light chain of an antibody. These sequences were under control of the CMV-promoter. The plasmid also included

EP 2 396 410 B1

SV40E polyA tails and the glutamate synthetase selection marker.

[0132] In example 5 and 6 single gene vectors were used containing sequences encoding either the heavy or the light chain of the monoclonal antibody. No selection marker was present on the plasmid. The single gene vectors were co-transfected at a 1:1 ratio.

[0133] Lipofectamine transfections were done using Lipofectamine2000 (Invitrogen). 12.5ul Lip2000 was diluted into 125ul serum free Dulbecco's modified Eagle's media (SF DMEM, Invitrogen). 4µg of the mAb expression vector DNA was diluted into 125ul SF DMEM. DNA and Lip2000 were mixed and incubated for 20 minutes at room temperature. 500ul SF DMEM was added to the mix which was then added to the cells to incubate at 37°C for four hours. Subsequent to incubation, the media containing the DNA/reagent mix was replaced by 3ml of fresh CDCHO media (Invitrogen). MAb transfections were done in duplicate.

[0134] Antibodies used in the examples were IgG antibodies of the following isotypes show in Table 1 below:

Table 1:

mAb	Species	Isotype	Extinction Coefficient
146	Mouse	IgG1	
632	Mouse	IgG2a	
497	Human	IgG4	
240	Human	IgG4	
42	Mouse	IgG1	1.6
61	Mouse	IgG1	1.62
164	Mouse	IgG1	1.6

[0135] Levels of antibody expression were determined by ELISA unless otherwise stated.

[0136] Cell density and cell viability was measured using CEDEX (Innovatis) automated cell counting system based on the well-established Trypan Blue exclusion method for determining cell viability. Sample handling, staining, cell counting and graphical analysis of the results are performed automatically by the CEDEX system.

Example 1: Transfection of CHO Cells with Erola and/or XBP1

CHOSX cell line

[0137] The spliced form of human XBP1 [hXBP1(s)] was cloned into vector pcDNA3.1(+), this vector also contained the G418 selection system comprising the neomycin resistance gene, which generated the vector pcDNA3.hXBP1(s). CHOS cells were transfected with vector pcDNA3.hXBP1(s) and stable cell lines were selected in the presence of geneticin (1 mg/ml) to produce a CHOSX cell line expressing hXBP1(s).

CHOK1E cell line

[0138] Human Ero1 α (hEro1 α) was cloned into the pcDNA3.1(+) vector and CHOK cells were transfected with pcDNA3.hEro1 α to produce a CHOK1E cell line expressing human Erola. CHOK1E cells were selected using the G418 selection system.

CHOSXE cell line

[0139] Human Ero1 α (hEro1 α) was cloned into vector pcDNA3.1(+)(zeo) (Invitrogen) and the CHOSX cell line was then supertransfected with vector pcDNA3(zeo).hEro1 α to produce the CHOSXE cell line expressing both hEro1 α and hXBP1(s). Both the G418 selection system (neomycin resistance gene) and the zeocin selection system (zeocin resistance gene) were used to select successfully transfected CHOSXE cells. The cells were grown in 100-300 µg/ml of zeocin and 1mg/ml of geneticin.

Selection of CHOSXE clones*Pick 1:*

5 [0140] Two weeks post transfection a first pick of 177 clones was performed of which 85 clones were positive for mRNA expression of the transgenes hEro1 α and hXBP1(s) as assessed by single cell RT-PCR and PCR.
 [0141] 24 of the 85 positive clones were then bulked up to 6-well plates. Relative mRNA levels of hXBP1(s) and hEro1 α were determined by Taqman. The results of this analysis are shown in Figures 3a and 3b where the relative hXBP1(s) and hEro1 α mRNA levels in the CHOSXE clones are compared to CHOS cells (CHOS cells showed no expression but counted as 1 for the purpose of calculating relative mRNA amounts). Using the results shown in Figures 3a and 3b, 3 low hEro1 α expressing clones (70, 77 and 103), 3 medium hEro1 α expressing clones (76, 88 and 173) and 3 high hEro1 α expressing clones (86, 94 and 101) were then selected for further analysis.

Pick 2:

15 [0142] A further two weeks after pick 1 was performed 72 more clones were picked of which 29 clones were positive for hXBP1(s) and hEro1 α mRNA expression as assessed by RT-PCR and PCR.
 [0143] The 29 positive clones were then bulked up to 6-well plates and relative levels of hXBP1(s) and hEro1 α mRNA were determined as in pick 1. The results of this analysis are shown in Figure 4 where the mRNA levels of hXBP1(s) and hEro1 α expressed in the CHOSXE clones are compared to CHOS cells (CHOS cells showed no expression but counted as 1 for the purpose of calculating relative mRNA amounts). Further mRNA analysis of clone 71 (data not shown) showed mRNA levels of 5,000 fold increase of hXBP1(s) and 110,000 fold increase of hEro1 α compared to CHOS cells (CHOS cells showed no expression but counted as 1 for the purpose of calculating relative mRNA amounts). Using the results shown in Figure 4, 3 low hEro1 α expressing clones (19, 23, and 64), 3 medium hEro1 α expressing clones (13, 16 and 62) and 3 high hEro1 α expressing clones (49, 57 and 71) were then selected for further analysis.
 [0144] Clone 71 was deposited under Depositor Deposit Name: CHOSXE (Depositor Identification in Full: CHOS.Xbp1.Ero1 α), on 10th February 2010 by UCB Celltech, the UK branch of UCB Pharma S.A., at the European Collection of Cell Cultures (ECACC), HPA, United Kingdom, under HPA Culture Collections Reference Number: Q8515 and Accession number: 10021001 in accordance with The Budapest Treaty.

Example 2: Transfection of CHOSXE cells with Monoclonal Antibodies (mAbs)

[0145] The selected clones from pick 1 (70, 76, 77, 86, 88, 94, 101, 103 and 173) were transfected with DNA of mAbs 146 and 632 as described in the methods and the mAb expression was determined from culture supernatant. The 3 highest mAb expressing CHOSXE clones were selected for further analysis (clones 70, 88 and 103).
 [0146] The three selected clones from pick 1 (70, 88, and 103) were then combined with the selected clones from pick 2 (13, 16, 19, 23, 49, 57, 62, 64, and 71) and transfected with DNA for mAbs 632 and 497 as described in the general methods section above. Culture supernatant sample was taken on day 4 to determine antibody concentration.
 [0147] Monoclonal antibodies 632 and 497 were also transfected into CHOS and CHOSX cells using the same transfection method as described in the general methods section above.
 [0148] The data for the relative increase in expression of mAbs 632 and 497 from CHOSXE and CHOSX cells compared to the expression of mAbs 632 and 497 from CHOS cells is shown in Figure 5. The data indicates that all the CHOSXE clones, except for clone 13 and clones 23, produced increased mAb expression levels of mAb 632 compared to the CHOS clone and all the CHOSXE clones produced increased expression of mAb 497 compared to both the CHOS the CHOSX clones, except for clone 23 which expressed less mAb 497 than CHOSX.

Example 3: Transfection of CHOSXE cells with Antibodies Ab240 and Ab146

[0149] The highest mAb expressing clones (16, 19, 57, 62, 71 and 88) produced in Example 2 were picked to perform further mAb transfections. The experiment was scaled up to T25 flask cultures and the mAb 240 and 146 were used. The transfection was performed as described above in the general methods section, but 18.75 μ l Lip2000 was diluted into 1.875ml OPTI_MEM (Invitrogen) media. 7.5 μ g of antibody DNA was diluted into 1.875ml OPTI_MEM media. 3.75ml of OPTI_MEM media was added to the mix to add to the cells. After incubation at 37°C, 3.375ml CD CHO media was added to the flask. This transfection method was used for CHOSXE cells, CHOSX cells, CHOK1E cells and CHOS cells.
 [0150] The data for the increase in expression of mAbs 240 and 146 from CHOSXE, CHOSX and CHOK1E cells compared to the expression of mAbs 240 and 146 from CHOS cells is shown in Figure 6. In Figure 6 clones numbered 16, 19, 57, 62, 71 and 88 are CHOSXE clones. The data indicates that all the CHOSXE clones produced increased expression of both antibodies compared to CHOS cells, CHOSX cells and CHOK1E cells.

EP 2 396 410 B1

[0151] Clone 71 was selected for further analysis and is called CHOSXE in Examples 4 to 7.

Example 4: Measurement of Cell Line Characteristics in CHOSXE, CHOSX and CHOS cell lines

5 [0152] Cells from cell lines CHOSXE, CHOSX and CHOS were seeded at 2×10^5 /ml in 50mls CD CHO and cultured over 7 days on a shaking platform. As shown in Figure 7, the CHOSXE cell line outperformed the CHOS, CHOSX, CHOK1 and CHOK1E cell lines by reaching higher viable cell densities.

Example 5: Electroporation of Antibodies 42, 61 and 164 into CHOSXE, CHOSX and CHOS cell lines

10 [0153] 400ug DNA of an antibody was transfected into 3 different cell lines CHOS, CHOSX and CHOSXE. Cells were shifted to 32°C on day 1 and 3 μ M NaBu added on day 4 post-transfection. The three antibodies used were labelled as mAbs 42, 61 and 164. Cell counts and cell viabilities were taken on day 1, 4, 7 and 10. Culture supernatant samples were taken on days 4, 7 and 10 to determine cells' specific productivity.

Table 2: % Cell viabilities and viable cell densities (VCD) on day 1 post-transfection.

Antibody	Cell Line	VCD cells x 10^5 /ml (day 1)	% Viability (day 1)
42	CHOS 42	22.7	96.7
42	CHOSX 42	23.85	96.8
42	CHOSXE 42	23.05	97.1
61	CHOS 61	23.4	96.8
61	CHOSX 61	20.14	96.9
61	CHOSXE 61	23.54	97.8
164	CHOS 164	20.92	97.5
164	CHOSX 164	22.04	96.5
164	CHOSXE 164	23.73	97.5

[0154] It can be seen from Table 2 that CHOXE cell lines had equal or higher % viability compared to CHOS and CHOSX and that CHOSXE had comparable viable cell densities compared to CHOS and CHOSX.

35 [0155] Figure 8 shows the relative increase in expression of mAbs 42, 61 and 164 from CHOSXE and CHOSX compared to the expression of mAbs 42, 61 and 164 from CHOS cells. It is clear that expression of all three antibodies was higher in CHOSXE compared to either CHOSX or CHOS.

[0156] The specific productivity rate (SPR) of each cell line was also calculated. Figure 9 shows the SPR of CHOS, CHOSX and CHOSXE cell lines in μ g/ 1×10^6 cells/day between day 4 and day 7. Specific productivity rate per cell was clearly higher in CHOSXE compared to either CHOS or CHOSX cell lines.

[0157] The relative mRNA levels of heavy and kappa light chains of the mAbs 42, 61 and 164 were also measured by real time PCR (Taqman). The results are shown in Figure 10, it can be seen that CHOSXE produced higher levels of the heavy and light chain mRNA compared to CHOS and CHOSX.

Example 6: Electroporation of Antibodies into CHOSXE, CHOSX, CHOS and CHOK1 cell lines and subsequent purification

[0158] CHOS, CHOSX, CHOSXE and CHOK1 cells were transfected as outlined in example 5.

50 [0159] MAb quantification was done by high-performance liquid affinity chromatography (HPLC) utilizing Protein G as a ligand. A standard curve was generated by injecting known amounts of purified IgG and analyzing the elution peaks. mAb eluate was monitored at 280nm and extrapolated from the standard curve to calculate the mAbs' concentrations using their respective extinction coefficients (concentration = absorbance/extinction coefficient) (Table 1).

[0160] mAbs were purified using MabSelect Sure columns. The protein-A derived MabSelect Sure ligand is derived from *E. coli* and has been engineered to create an affinity medium with enhanced alkali stability and high binding capacity for IgG. At this point a trace HPLC was done to determine the percentage aggregate of the affinity-purified pooled fractions. The degree of aggregation exhibited by mAbs expressed in CHOSXE was comparable to CHOS, CHOSX and CHOK1 (see Figure 11). Following MabSelect Sure, antibodies were further purified using size exclusion HPLC. The total mAb yield post-purification was also determined by reading absorbance of the mAb at 280nm and calculating

concentration as above.

[0161] Table 3 shows increases in antibody concentration relative to the CHOS cells after prot G HPLC and protein purification.

Table 3:

		Fold increase	
		Prot G HPLC	Yield after Purification
Ab42	CHOS	1.00	1.00
	CHOSX	1.09	0.83
	CHOSXE	6.28	7.22
	CHOK1	1.65	2.70
Ab61	CHOS	1.00	1.00
	CHOSX	2.39	3.30
	CHOSXE	5.36	5.24
	CHOK1	1.58	2.35
Ab164	CHOS	1.00	1.00
	CHOSX	2.68	2.44
	CHOSXE	5.94	6.14
	CHO K1	1.94	2.80

[0162] It can be seen from Table 3 that the CHOSXE cells produced a significantly higher quantity of antibody compared to CHOS, CHOSX and CHOK1 cells.

Example 7 Antibody Quality Analysis

[0163] Purified mAbs from CHOSXE cells were analyzed for quality and activity as described below.

Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS PAGE)

[0164] MAbs 42, 61 and 164 were analyzed by SDS PAGE to determine whether the expressed antibody was of the expected size. The SDS PAGE analysis was performed by running 5 μ g of reduced and non-reduced protein on a pre-packed 4-12% Bis-Tris gradient gel (Invitrogen) at 50mA for 45 minutes. Figures 12a, b and c show the results of the SDS PAGE, it can be seen that the antibodies were the same size whether expressed from CHOS, CHOSX, CHOSXE or CHOK1.

Thermofluor assay

[0165] The thermostability of MAbs 42, 61 and 164 were analyzed in a Thermofluor assay. This assay allows one to determine at which temperature the protein structure becomes unfolded. An environmentally sensitive fluorescent dye was used to monitor the thermal unfolding process of the proteins. The dye binds hydrophobic regions that become exposed upon unfolding and changes its emission spectrum. 1 μ l of sample at 1 mg/ml, 1 μ l of 30x dye, and 8 μ l of buffer was placed into a well of a 384 PCR optical well plate (samples run in quadruplicate). 7900HT fast real-time PCR system contains a heating device for accurate temperature control set at 20°C to 99°C, a CCD device simultaneously monitors the fluorescence changes in the wells. Standard deviations were less than 0.5°C, for the thermofluor assay data presented. The results from the Thermofluor assay are shown in Figure 13 where it can be seen that there were no significant differences between the thermostability properties of mAbs when expressed from CHOS or CHOSXE.

Iso-electric focussing

[0166] MAb 42, 61 and 164 were analyzed by Iso-electric focussing to determine if the expressed antibodies had the same net charge. High voltage was applied across the capillary using anode and cathode, which were dipped, in small

reservoirs containing catholyte (OH⁻) and anolyte (H⁺). Samples were prepared with carrier ampholytes and on application of high voltage the protein molecules migrated and focused according to their respective pI's. The system used was the ICE 280 from Convergent biosciences (Isogen in Europe) which is an imaged capillary isoelectrophoresis instrument used to determine pI's of various protein samples and their related species. The results showed no major differences between the charges antibodies expressed in CHOK1SV, CHOS and CHOSXE.

Mass spectrometry

[0167] The glycosylation profiles of mAbs 42, 61 and 164 were analyzed by mass spectrometry. 100µg of each sample was treated with PNGase under native conditions to release N-glycans. Glycan separated from deglycosylated protein by SEC and the glycan fraction was analysed by MALDI Mass Spec. This analysis determined if the expressed antibodies had the same glycosylation profiles and whether any unfavourable sugar moieties had bound to the antibodies. The results from the glycosylation profiles are shown in Figure 14 show that there were no significant differences between the glycosylation profiles of the antibodies expressed from CHOS and CHOSXE.

Antigen binding assay

[0168] MAb164 was analyzed in an antigen binding assay to determine if the expressed antibody had the same antigen binding affinity. BALB/C splenocytes expressing the target antigen of mAb 164 were treated with a titration of mAb 164. Cells were washed and treated with a PE labeled anti-mouse IgG1. Fluorescence cell staining was determined using FACS. The results from the assay are shown in Figure 15 where "Geo mean" is the geometric mean value of fluorescence of antibody binding. MOPC21 is anti-mouse IgG1 antibody and used as a negative control. Figure 15 shows that mAb 164 expressed from CHOSXE did not have significantly different antigen binding activity compared to the antibody expressed from CHOS.

[0169] In view of the above, it is clear that the antibodies expressed from CHOSXE did not exhibit any major differences from the antibodies expressed from other cell lines. Accordingly, the cell according to the present invention is capable of expressing a protein of interest, such as an antibody, having the same properties compared to when the protein is expressed in other cells, specifically cells which have not been modified to over express Ero1 and XBP1.

[0170] It will of course be understood that the present invention has been described by way of example only, is in no way meant to be limiting, and that modifications of detail can be made within the scope of the claims hereinafter. Preferred features of each embodiment of the invention are as for each of the other embodiments *mutatis mutandis*. All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.

SEQUENCE LISTING

[0171]

<110> UCB Pharma SA

<120> Method for Expressing Protein

<130> G0080_Wo01

<150> GB0902180.9

<151> 2009-02-10

<160> 4

<170> PatentIn version 3.5

<210> 1

<211> 376

<212> PRT

<213> Human XBP1

<400> 1

EP 2 396 410 B1

Met Val Val Val Ala Ala Ala Pro Asn Pro Ala Asp Gly Thr Pro Lys
1 5 10 15

5 Val Leu Leu Leu Ser Gly Gln Pro Ala Ser Ala Ala Gly Ala Pro Ala
20 25 30

Gly Gln Ala Leu Pro Leu Met Val Pro Ala Gln Arg Gly Ala Ser Pro
35 40 45 10

Glu Ala Ala Ser Gly Gly Leu Pro Gln Ala Arg Lys Arg Gln Arg Leu
50 55 60 15

Thr His Leu Ser Pro Glu Glu Lys Ala Leu Arg Arg Lys Leu Lys Asn
65 70 75 80

Arg Val Ala Ala Gln Thr Ala Arg Asp Arg Lys Lys Ala Arg Met Ser
85 90 95 20

Glu Leu Glu Gln Gln Val Val Asp Leu Glu Glu Glu Asn Gln Lys Leu
100 105 110 25

Leu Leu Glu Asn Gln Leu Leu Arg Glu Lys Thr His Gly Leu Val Val
115 120 125

Glu Asn Gln Glu Leu Arg Gln Arg Leu Gly Met Asp Ala Leu Val Ala
130 135 140 30

Glu Glu Glu Ala Glu Ala Lys Gly Asn Glu Val Arg Pro Val Ala Gly
145 150 155 160

Ser Ala Glu Ser Ala Ala Gly Ala Gly Pro Val Val Thr Pro Pro Glu
165 170 175 35

40

45

50

55

EP 2 396 410 B1

His Leu Pro Met Asp Ser Gly Gly Ile Asp Ser Ser Asp Ser Glu Ser
 180 185 190
 5 Asp Ile Leu Leu Gly Ile Leu Asp Asn Leu Asp Pro Val Met Phe Phe
 195 200 205
 10 Lys Cys Pro Ser Pro Glu Pro Ala Ser Leu Glu Glu Leu Pro Glu Val
 210 215 220
 Tyr Pro Glu Gly Pro Ser Ser Leu Pro Ala Ser Leu Ser Leu Ser Val
 225 230 235 240
 15 Gly Thr Ser Ser Ala Lys Leu Glu Ala Ile Asn Glu Leu Ile Arg Phe
 245 250 255
 Asp His Ile Tyr Thr Lys Pro Leu Val Leu Glu Ile Pro Ser Glu Thr
 260 265 270
 20 Glu Ser Gln Ala Asn Val Val Val Lys Ile Glu Glu Ala Pro Leu Ser
 275 280 285
 25 Pro Ser Glu Asn Asp His Pro Glu Phe Ile Val Ser Val Lys Glu Glu
 290 295 300
 30 Pro Val Glu Asp Asp Leu Val Pro Glu Leu Gly Ile Ser Asn Leu Leu
 305 310 315 320
 Ser Ser Ser His Cys Pro Lys Pro Ser Ser Cys Leu Leu Asp Ala Tyr
 325 330 335
 35 Ser Asp Cys Gly Tyr Gly Gly Ser Leu Ser Pro Phe Ser Asp Met Ser
 340 345 350
 40 Ser Leu Leu Gly Val Asn His Ser Trp Glu Asp Thr Phe Ala Asn Glu
 355 360 365
 Leu Phe Pro Gln Leu Ile Ser Val
 370 375

45 <210> 2
 <211> 1132
 <212> DNA
 <213> Human XBP1

50 <400> 2

aatggtggtg gtggcagccg cgccgaaccc ggccgacggg acccctaaag ttctgcttct
60

55 gtcggggcag cccgcctccg ccgccggagc cccggccggc caggccctgc cgctcatggt
120

gccagcccag agaggggcca gcccgaggc agcgagcggg gggctgcccc aggcgcgcaa
180

EP 2 396 410 B1

gcgacagcgc ctcacgcacc tgagccccga ggagaaggcg ctgaggagga aactgaaaaa
240

5 cagagtagca gctcagactg ccagagatcg aaagaaggct cgaatgagtg agctggaaca
300

gcaagtggta gatttagaag aagagaacca aaaacttttg ctagaaaatc agcttttacg
360

10 agagaaaact catggccttg tagttgagaa ccaggagtta agacagcgct tggggatgga
420

tgccctggtt gctgaagagg aggcggaagc caaggggaat gaagtgaggc cagtggccgg
480

15 gtctgtgag tccgcagcag gtgcaggccc agttgtcacc cctccagaac atctccccat
540

ggattctggc ggtattgact cttcagattc agagtctgat atcctgttgg gcattctgga
600

20 caacttgac ccagtcatgt tcttcaaatg cccttcccca gagcctgcca gcctggagga
660

gctcccagag gtctaccag aaggaccag ttccttacca gcctcccttt ctctgtcagt
720

25 ggggacgtca tcagccaagc tggaagccat taatgaacta attcgttttg accacatata
780

taccaagccc ctagtcttag agatacctc tgagacagag agccaagcta atgtggtagt
840

30 gaaaatcgag gaagcacctc tcagcccctc agagaatgat caccctgaat tcattgtctc
900

agtgaaggaa gaacctgtag aagatgacct cgttccggag ctgggtatct caaatctgct
960

35 ttcattccagc cactgccc aaagccatcttc ctgcctactg gatgcttaca gtgactgtgg
1020

ataggggggt tccctttccc cattcagtga catgtcctct ctgcttggtg taaaccattc
1080

40 ttgggaggac acttttgcca atgaactctt tccccagctg attagtgtct aa
1132

<210> 3
 <211> 468
 <212> PRT
 45 <213> Human Ero1alpha
 <400> 3

50 Met Gly Arg Gly Trp Gly Phe Leu Phe Gly Leu Leu Gly Ala Val Trp
 1 5 10 15

Leu Leu Ser Ser Gly His Gly Glu Glu Gln Pro Pro Glu Thr Ala Ala
 20 25 30

55 Gln Arg Cys Phe Cys Gln Val Ser Gly Tyr Leu Asp Asp Cys Thr Cys

EP 2 396 410 B1

	35					40						45				
5	Asp	Val	Glu	Thr	Ile	Asp	Arg	Phe	Asn	Asn	Tyr	Arg	Leu	Phe	Pro	Arg
	50					55					60					
	Leu	Gln	Lys	Leu	Leu	Glu	Ser	Asp	Tyr	Phe	Arg	Tyr	Tyr	Lys	Val	Asn
	65					70					75					80
10	Leu	Lys	Arg	Pro	Cys	Pro	Phe	Trp	Asn	Asp	Ile	Ser	Gln	Cys	Gly	Arg
					85					90					95	
	Arg	Asp	Cys	Ala	Val	Lys	Pro	Cys	Gln	Ser	Asp	Glu	Val	Pro	Asp	Gly
15				100					105					110		
	Ile	Lys	Ser	Ala	Ser	Tyr	Lys	Tyr	Ser	Glu	Glu	Ala	Asn	Asn	Leu	Ile
			115					120					125			
20	Glu	Glu	Cys	Glu	Gln	Ala	Glu	Arg	Leu	Gly	Ala	Val	Asp	Glu	Ser	Leu
		130					135					140				
	Ser	Glu	Glu	Thr	Gln	Lys	Ala	Val	Leu	Gln	Trp	Thr	Lys	His	Asp	Asp
25	145					150					155					160
	Ser	Ser	Asp	Asn	Phe	Cys	Glu	Ala	Asp	Asp	Ile	Gln	Ser	Pro	Glu	Ala
					165					170					175	
30	Glu	Tyr	Val	Asp	Leu	Leu	Leu	Asn	Pro	Glu	Arg	Tyr	Thr	Gly	Tyr	Lys
				180					185					190		
	Gly	Pro	Asp	Ala	Trp	Lys	Ile	Trp	Asn	Val	Ile	Tyr	Glu	Glu	Asn	Cys
35			195					200					205			
	Phe	Lys	Pro	Gln	Thr	Ile	Lys	Arg	Pro	Leu	Asn	Pro	Leu	Ala	Ser	Gly
		210					215					220				
40	Gln	Gly	Thr	Ser	Glu	Glu	Asn	Thr	Phe	Tyr	Ser	Trp	Leu	Glu	Gly	Leu
	225					230					235					240
	Cys	Val	Glu	Lys	Arg	Ala	Phe	Tyr	Arg	Leu	Ile	Ser	Gly	Leu	His	Ala
45					245					250					255	
	Ser	Ile	Asn	Val	His	Leu	Ser	Ala	Arg	Tyr	Leu	Leu	Gln	Glu	Thr	Trp
				260					265					270		
50	Leu	Glu	Lys	Lys	Trp	Gly	His	Asn	Ile	Thr	Glu	Phe	Gln	Gln	Arg	Phe
			275					280					285			
	Asp	Gly	Ile	Leu	Thr	Glu	Gly	Glu	Gly	Pro	Arg	Arg	Leu	Lys	Asn	Leu
55		290					295					300				

EP 2 396 410 B1

Tyr Phe Leu Tyr Leu Ile Glu Leu Arg Ala Leu Ser Lys Val Leu Pro
 305 310 315 320
 5 Phe Phe Glu Arg Pro Asp Phe Gln Leu Phe Thr Gly Asn Lys Ile Gln
 325 330 335
 10 Asp Glu Glu Asn Lys Met Leu Leu Leu Glu Ile Leu His Glu Ile Lys
 340 345 350
 Ser Phe Pro Leu His Phe Asp Glu Thr Ser Phe Phe Ala Gly Asp Lys
 355 360 365
 15 Lys Glu Ala His Lys Leu Lys Glu Asp Phe Arg Leu His Phe Arg Asn
 370 375 380
 20 Ile Ser Arg Ile Met Asp Cys Val Gly Cys Phe Lys Cys Arg Leu Trp
 385 390 395 400
 Gly Asn Leu Gln Thr Gln Gly Leu Gly Thr Ala Leu Lys Ile Leu Phe
 405 410 415
 25 Ser Glu Lys Leu Ile Ala Asn Met Pro Glu Ser Gly Pro Ser Tyr Glu
 420 425 430
 30 Phe His Leu Thr Arg Gln Glu Ile Val Ser Leu Phe Asn Ala Phe Gly
 435 440 445
 Arg Ile Ser Thr Ser Val Lys Glu Leu Glu Asn Phe Arg Asn Leu Leu
 450 455 460
 35 Gln Asn Ile His
 465

<210> 4

<211> 1407

40 <212> DNA

<213> Human Ero1alpha

<400> 4

45 atgggccg gctggggatt cttgtttggc ctctgggcg ccgtgtggct gctcagctcg
 60
 ggccacggag aggagcagcc cccggagaca gcggcacaga ggtgcttctg ccaggttagt
 120
 50 ggttacttgg atgattgtac ctgtgatggt gaaaccattg atagatttaa taactacagg
 180
 cttttcccaa gactacaaaa acttcttgaa agtgactact ttaggtatta caaggtaaac
 240
 55 ctgaagaggc cgtgtccttt ctggaatgac atcagccagt gtggaagaag ggactgtgct
 300

gtcaaaccat gtcaatctga tgaagttcct gatggaatta aatctgcgag ctacaagtat
360

tctgaagaag ccaataatct cattgaagaa tgtgaacaag ctgaacgact tggagcagtg
420

gatgaatctc tgagtgagga aacacagaag gctgttcttc agtggacca gcatgatgat
480

tcttcagata acttctgtga agctgatgac attcagtccc ctgaagctga atatgtagat
540

ttgcttctta atcctgagcg ctacactggc tacaagggac cagatgcttg gaaaatatgg
600

aatgtcatct acgaagaaaa ctgttttaag ccacagacaa ttaaaagacc tttaaatcct
660

ttggcttctg gtcaagggac aagtgaagag aacacttttt acagttggct agaaggtctc
720

tgtgtagaaa aaagagcatt ctacagactt atatctggcc tacatgcaag cattaatgtg
780

catttgagtg caagatatct tttacaagag acctgggttag aaaagaaatg gggacacaac
840

attacagaat ttcaacagcg atttgatgga attttgactg aaggagaagg tccaagaagg
900

cttaagaact tgtatcttct ctacttaata gaactaaggg ctttatccaa agtgttacca
960

ttcttcgagc gccagatct tcaactcttt actggaaata aaattcagga tgaggaaaac
1020

aaaatgttac ttctggaat acttcatgaa atcaagtcatt ttcctttgca ttttgatgag
1080

acttcatttt ttgctgggga taaaaaagaa gcacacaaac taaaggagga ctttcgactg
1140

cattttagaa atatttcaag aattatggat tgtgttggtt gttttaaatg tcgtctgtgg
1200

ggaaatcttc agactcaggg tttgggcact gctctgaaga tcttattttc tgagaaattg
1260

atagcaaata tgccagaaag tggacctagt tatgagttcc atctaaccag acaagaaata
1320

gtatcattat tcaacgcatt tggaagaatt tctacaagtg tgaaagaatt agaaaacttc
1380

aggaacttgt tacagaatat tcattaa
1407

Claims

1. A recombinant host cell, wherein the cell is modified to comprise an exogenous polynucleotide sequence encoding Ero1 comprising the polypeptide sequence given in SEQ ID NO: 3 or a variant thereof which substantially retains the function of Ero1; and an exogenous polynucleotide sequence encoding XBP1 comprising the polypeptide sequence given in SEQ ID NO:1 or a variant thereof which substantially retains the function of XBP1 and said modified host cell has increased expression levels of Ero1 and XBP1 relative to the expression levels of Ero1 and XBP1 in an unmodified cell.

EP 2 396 410 B1

2. A cell according to claim 1, wherein the cell comprises an Ero1 and XBP1 polynucleotide comprising both the polynucleotide sequence encoding Ero1 or a variant thereof which substantially retains the function of Ero1; and the polynucleotide sequence encoding XBP1 or a variant thereof which substantially retains the function of XBP1.
- 5 3. A cell according to claim 1, wherein the cell comprises an Ero1 polynucleotide comprising the polynucleotide sequence encoding Ero1 or a variant thereof which substantially retains the function of Ero1 and a separate XBP1 polynucleotide comprising the polynucleotide sequence encoding XBP1 or a variant thereof which substantially retains the function of XBP1.
- 10 4. A cell according to any of claims 1 to 3, wherein the polynucleotide sequence encoding Ero1 encodes human, mouse or hamster Ero1.
5. A cell according to claim 4, wherein the polynucleotide sequence encoding Ero1 encodes human Ero1 and is Ero1 α or Ero1 β .
- 15 6. A cell according to claim 5, wherein the polynucleotide sequence encoding Ero1 encodes Ero1 α and comprises the sequence given in SEQ ID NO: 4.
- 20 7. A cell according to claim 5 or claim 6, wherein the polynucleotide sequence encoding Ero1 encodes the polypeptide sequence given in SEQ ID NO: 3.
8. A cell according to any of claims 1 to 7, wherein the polynucleotide sequence encoding XBP1 encodes human, mouse or hamster XBP1.
- 25 9. A cell according to claim 8, wherein the polynucleotide sequence encoding XBP1 encodes human XBP1 and comprises the sequence given in SEQ ID NO: 2.
- 30 10. A cell according to claim 8 or claim 9, wherein the polynucleotide sequence encoding XBP1 encodes human XBP1 and encodes the polypeptide sequence given in SEQ ID NO:1.
- 35 11. A cell according to any preceding claim, wherein the cell further comprises a polynucleotide sequence encoding a protein of interest.
12. A cell according to claim 11, wherein the protein of interest is an antibody or an antigen binding fragment thereof.
- 40 13. A cell according to any preceding claim, wherein the cell is a mammalian cell.
14. A cell according to claim 13, wherein the cell is a CHO cell.
- 45 15. A CHOSXE cell line as deposited on 10th February 2010 (Depositor Identification in Full:
CHOS.Xbp1.Ero1a), at the European Collection of Cell Cultures (ECACC), HPA, United Kingdom, under HPA Culture Collections Reference Number: Q8515 and Accession number: 10021001 in accordance with The Budapest Treaty.
- 50 16. A method of modifying a host cell to increase the capability of the host cell to express protein comprising increasing the expression levels of Ero1 polypeptide or a variant thereof which substantially retains the function of Ero1 and XBP1 polypeptide or a variant thereof which substantially retains the function of XBP1 in the host cell relative to the expression levels of Ero1 and XBP1 in an unmodified cell, wherein the method comprises transfecting the cell with one or more polynucleotides, as defined in any of claims 1 to 10.
- 55 17. A method according to claim 16, wherein the method comprises a further step of culturing the modified cell in a medium to thereby express increased levels of Ero1 polypeptide or a variant thereof which substantially retains the function of Ero1; and XBP1 polypeptide or a variant thereof which substantially retains the function of XBP1 compared to an unmodified cell.
18. A method according to claim 17, wherein the method further comprises the following steps:

- a. selecting one or more modified cell clones;
b. measuring the quantity of Ero1 mRNA and/or protein in the selected one or more cell clones;
c. measuring the quantity of XBP1 mRNA and/or protein in the selected one or more clones;
d. comparing the quantity of Ero1 mRNA and/or protein and XBP1 mRNA and/or protein to the quantity of Ero1 mRNA and/or protein and XBP1 mRNA and/or protein in an unmodified cell clone; and
e. selecting one or more modified cell clones having a higher quantity of Ero1 mRNA and/or protein and XBP1 mRNA and/or protein compared to the unmodified cell clone.
- 5
19. A method according to any of claims 16 to 18, wherein the method further comprises transfecting the host cell with a polynucleotide sequence encoding a protein of interest and expressing the protein of interest.
- 10
20. A method of producing a recombinant protein of interest comprising expressing the recombinant protein of interest in a modified host cell in which the expression levels of XBP1 and Ero1 are increased relative to the expression levels of Ero1 and XBP1 in an unmodified cell, wherein the host cell is as defined in any of claims 11 to 15.
- 15
21. An isolated polynucleotide comprising a polynucleotide sequence encoding Ero1 or a variant thereof which substantially retains the function of Ero1; and a polynucleotide sequence encoding XBP1 or a variant thereof which substantially retains the function of XBP1, wherein the polynucleotide is as defined in any of claims 4 to 10.
- 20
22. An isolated polynucleotide according to claim 21 wherein the polynucleotide further comprises a polynucleotide sequence encoding a protein of interest.
23. An expression cassette comprising the polynucleotide as defined in any of claims 21 to 22.
- 25
24. A vector comprising the polynucleotide as defined in any of claims 21 to 22 or an expression cassette as defined in claim 23.
- 30
25. An expression system comprising a recombinant polynucleotide sequence encoding Ero1 or a variant thereof which substantially retains the function of Ero1; a recombinant polynucleotide sequence encoding XBP1 or a variant thereof which substantially retains the function of XBP1; and a medium; wherein the expression system comprises a polynucleotide as defined in any of claims 21 to 22, an expression cassette as defined in claim 23 or a vector as defined in claim 24.
- 35
26. An expression system according to claim 25, wherein the expression system comprises the Ero1 and XBP1 polynucleotides as defined in claim 3
27. An expression system according to any of claims 25 or 26, wherein the expression system comprises a cell as defined in any of claims 1 to 15.
- 40
28. A polynucleotide as defined in any of claims 21 to 22, an expression cassette as defined in claim 23, a vector as defined in claim 24, a cell as defined in any of claims 1 to 15 or an expression system as defined in any of claims 25 or 26 for use as a medicament.
- 45
29. Use of a recombinant polynucleotide sequence encoding Ero1 comprising the polypeptide sequence given in SEQ ID NO: 3 and a recombinant polynucleotide sequence encoding XBP1 comprising the polypeptide sequence given in SEQ ID NO: 1 for expressing a protein of interest.

Patentansprüche

- 50
1. Rekombinante Wirtszelle, wobei die Zelle so modifiziert ist, dass sie eine exogene Polynukleotidsequenz, die Ero1 codiert, umfassend die in SEQ ID NO: 3 angegebene Polypeptidsequenz oder eine Variante davon, die im Wesentlichen die Funktion von Ero1 beibehält; sowie eine exogene Polynukleotidsequenz umfasst, die XBP1 codiert, umfassend die in SEQ ID NO: 1 angegebene Polypeptidsequenz oder eine Variante davon, die im Wesentlichen die Funktion von XBP1 behält, und die modifizierte Wirtszelle erhöhte Expressionsspiegel von Ero1 und XBP1 relativ zu den Expressionsspiegeln von Ero1 und XBP1 in einer unmodifizierten Zelle hat.
- 55
2. Zelle nach Anspruch 1, wobei die Zelle ein Ero1- und XBP1-Polynukleotid umfasst, das die Polynukleotidsequenz,

EP 2 396 410 B1

die Ero1 oder eine Variante davon codiert, die im Wesentlichen die Funktion von Ero1 beibehält; und die Polynukleotidsequenz umfasst, die XBP1 oder eine Variante davon codiert, die im Wesentlichen die Funktion von XBP1 beibehält.

- 5 **3.** Zelle nach Anspruch 1, wobei die Zelle ein Ero1-Polynukleotid, umfassend die Polynukleotidsequenz, die Ero1 oder eine Variante davon codiert, die im Wesentlichen die Funktion von Ero1 beibehält, und ein separates XBP1-Polynukleotid umfasst, umfassend die Polynukleotidsequenz, die XBP1 oder eine Variante davon codiert, die im Wesentlichen die Funktion von XBP1 beibehält.
- 10 **4.** Zelle nach einem der Ansprüche 1 bis 3, wobei die Polynukleotidsequenz, die Ero1 codiert, Human-, Maus- oder Hamster-Ero1 codiert.
- 5.** Zelle nach Anspruch 4, wobei die Polynukleotidsequenz, die Ero1 codiert, Human-Ero1 codiert, und es sich dabei um Ero1□ oder Ero1□ handelt.
- 15 **6.** Zelle nach Anspruch 5, wobei die Polynukleotidsequenz, die Ero1 codiert, Ero1□ codiert und die in SEQ ID NO: 4 angegebene Sequenz umfasst.
- 7.** Zelle nach Anspruch 5 oder Anspruch 6, wobei die Polynukleotidsequenz, die Ero1 codiert, die in SEQ ID NO: 3 angegebene Polypeptidsequenz codiert.
- 20 **8.** Zelle nach einem der Ansprüche 1 bis 7, wobei die Polynukleotidsequenz, die XBP1 codiert, Human-, Maus- oder Hamster-XBP1 codiert.
- 25 **9.** Zelle nach Anspruch 8, wobei die Polynukleotidsequenz, die XBP1 codiert, Human-XBP1 codiert und die in SEQ ID NO: 2 angegebene Sequenz umfasst.
- 10.** Zelle nach Anspruch 8 oder Anspruch 9, wobei die Polynukleotidsequenz, die XBP1 codiert, Human-XBP1 codiert und die in SEQ ID NO: 1 angegebene Polypeptidsequenz codiert.
- 30 **11.** Zelle nach einem vorhergehenden Anspruch, wobei die Zelle zudem eine Polynukleotidsequenz umfasst, die ein Protein von Interesse codiert.
- 12.** Zelle nach Anspruch 11, wobei das Protein von Interesse ein Antikörper oder ein Antigen-bindendes Fragment davon ist.
- 35 **13.** Zelle nach einem vorhergehenden Anspruch, wobei die Zelle eine Säugetierzelle ist.
- 14.** Zelle nach Anspruch 13, wobei die Zelle eine CHO-Zelle ist.
- 40 **15.** CHOSXE-Zelllinie, hinterlegt am 10. Februar 2010 (vollständige Hinterleger-Identifikation: CHOS.Xbp1.Ero1a) an der European Collection of Cell Cultures (ECACC), HPA, Vereinigtes Königreich, unter der HPA-Referenznummer der Kultursammlungen:
- 45 Q8515 und Zugangsnummer: 10021001 gemäß dem Budapester Vertrag.
- 16.** Verfahren zum Modifizieren einer Wirtszelle zur Steigerung der Fähigkeit der Wirtszelle, Protein zu exprimieren, umfassend das Steigern der Expressionsspiegel von Ero1-Polypeptid oder einer Variante davon, die im Wesentlichen die Funktion von Ero1 beibehält, und von XBP1-Polypeptid oder einer Variante davon, die im Wesentlichen die Funktion von XBP1 beibehält, in der Wirtszelle relativ zu den Expressionsspiegeln von Ero1 und XBP1 in einer unmodifizierten Zelle, wobei das Verfahren das Transfizieren der Zelle mit einem oder mehr Polynukleotiden nach einem der Ansprüche 1 bis 10 umfasst.
- 50 **17.** Verfahren nach Anspruch 16, wobei das Verfahren einen weiteren Schritt Züchten der modifizierten Zelle in einem Medium umfasst, wodurch erhöhte Spiegel an Ero1-Polypeptid oder einer Variante davon, die im Wesentlichen die Funktion von Ero1 beibehält; und an XBP1-Polypeptid oder einer Variante davon, die im Wesentlichen die Funktion von XBP1 beibehält, im Vergleich zu einer unmodifizierten Zelle exprimiert werden.
- 55

EP 2 396 410 B1

18. Verfahren nach Anspruch 17, wobei das Verfahren zudem die folgenden Schritte umfasst:

- a. Selektieren von einem oder mehr modifizierten Zellklonen;
- b. Messen der Menge an Ero1-mRNA und/oder -Protein in den selektierten ein oder mehr Zellklonen;
- c. Messen der Menge an XBP1-mRNA und/oder -Protein in den selektierten ein oder mehr Klonen;
- d. Vergleichen der Menge an Ero1-mRNA und/oder -Protein und XBP1-mRNA und/oder -Protein mit der Menge an Ero1-mRNA und/oder -Protein und XBP1-mRNA und/oder -Protein in einem unmodifizierten Zellklon; und
- e. Selektieren von einem oder mehr modifizierten Zellklonen mit einer höheren Menge an Ero1-mRNA und/oder -Protein und XBP1-mRNA und/oder -Protein im Vergleich zu dem unmodifizierten Zellklon.

19. Verfahren nach einem der Ansprüche 16 bis 18, wobei das Verfahren zudem das Transfizieren der Wirtszelle mit einer Polynukleotidsequenz, die ein Protein von Interesse codiert, und Expressieren des Proteins von Interesse umfasst.

20. Verfahren zur Herstellung eines rekombinanten Proteins von Interesse, umfassend das Expressieren des rekombinanten Proteins von Interesse in einer modifizierten Wirtszelle, in der die Expressionsspiegel von XBP1 und Ero1 relativ zu den Expressionsspiegeln von Ero1 und XBP1 in einer unmodifizierten Zelle erhöht sind, wobei die Wirtszelle nach einem der Ansprüche 11 bis 15 definiert ist.

21. Isoliertes Polynukleotid, umfassend eine Polynukleotidsequenz, die Ero1 oder eine Variante davon codiert, die im Wesentlichen die Funktion von Ero1 beibehält; und eine Polynukleotidsequenz, die XBP1 oder eine Variante davon codiert, die im Wesentlichen die Funktion von XBP1 beibehält; wobei das Polynukleotid nach einem der Ansprüche definiert ist.

22. Isoliertes Polynukleotid nach Anspruch 21, wobei das Polynukleotid zudem eine Polynukleotidsequenz umfasst, die ein Protein von Interesse codiert.

23. Expressionskassette, umfassend das Polynukleotid nach einem der Ansprüche 21 bis 22.

24. Vektor, umfassend das Polynukleotid nach einem der Ansprüche 21 bis 22 oder eine Expressionskassette nach Anspruch 23.

25. Expressionssystem, umfassend eine rekombinante Polynukleotidsequenz, die Ero1 oder eine Variante davon codiert, die im Wesentlichen die Funktion von Ero1 beibehält; eine rekombinante Polynukleotidsequenz, die XBP1 oder eine Variante davon codiert, die im Wesentlichen die Funktion von XBP1 beibehält; und ein Medium, wobei das Expressionssystem ein Polynukleotid nach einem der Ansprüche 21 bis 22, eine Expressionskassette nach Anspruch 23 oder einen Vektor nach Anspruch 24 umfasst.

26. Expressionssystem nach Anspruch 25, wobei das Expressionssystem die Ero1- und XBP1-Polynukleotide nach Anspruch 3 umfasst.

27. Expressionssystem nach einem der Ansprüche 25 oder 26, wobei das Expressionssystem eine Zelle nach einem der Ansprüche 1 bis 15 umfasst.

28. Polynukleotid nach einem der Ansprüche 21 bis 22, Expressionskassette nach Anspruch 23, Vektor nach Anspruch 24, Zelle nach einem der Ansprüche 1 bis 15 oder Expressionssystem nach einem der Ansprüche 25 oder 26 zur Verwendung als Arzneimittel.

29. Verwendung einer rekombinanten Polynukleotidsequenz, die Ero1 codiert, umfassend die in SEQ ID NO: 3 angegebene Polypeptidsequenz, und einer rekombinanten Polynukleotidsequenz, die XBP1 codiert, umfassend die in SEQ ID NO: 1 angegebene Polypeptidsequenz, zur Expression eines Proteins von Interesse.

Revendications

1. Cellule hôte recombinante, la cellule étant modifiée pour comprendre une séquence de polynucléotides exogène codant pour Ero1, comprenant la séquence de polypeptides donnée dans la SEQ ID n° : 3 ou un variant de celle-ci qui conserve substantiellement la fonction d'Ero1 ; et une séquence de polynucléotides exogène codant pour

EP 2 396 410 B1

XBP1, comprenant la séquence de polypeptides donnée dans la SEQ ID n° : 1 ou un variant de celle-ci qui conserve substantiellement la fonction de XBP1, et ladite cellule hôte modifiée a des niveaux d'expression accrus d'Ero1 et de XBP1 par rapport aux niveaux d'expression d'Ero1 et de XBP1 dans une cellule non modifiée.

- 5 **2.** Cellule selon la revendication 1, dans laquelle la cellule comprend un polynucléotide d'Ero1 et de XBP1 comprenant à la fois la séquence de polynucléotides codant pour Ero1 ou un variant de celle-ci, qui conserve substantiellement la fonction d'Ero1 ; et la séquence de polynucléotides codant pour XBP1 ou un variant de celle-ci, qui conserve substantiellement la fonction de XBP1.
- 10 **3.** Cellule selon la revendication 1, dans laquelle la cellule comprend un polynucléotide d'Ero1, comprenant la séquence de polynucléotides codant pour Ero1 ou un variant de celle-ci qui conserve substantiellement la fonction d'Ero1, et un polynucléotide de XBP1 séparé, comprenant la séquence de polynucléotides codant pour XBP1 ou un variant de celle-ci qui conserve substantiellement la fonction de XBP1.
- 15 **4.** Cellule selon l'une quelconque des revendications 1 à 3, dans laquelle la séquence de polynucléotides codant pour Ero1 code pour une Ero1 humaine, de souris ou de hamster.
- 5.** Cellule selon la revendication 4, dans laquelle la séquence de polynucléotides codant pour Ero1 code pour une Ero1 humaine et est une Ero1 α ou une Ero1 β .
- 20 **6.** Cellule selon la revendication 5, dans laquelle la séquence de polynucléotides codant pour Ero1 code pour une Ero1 α et comprend la séquence donnée dans la SEQ ID n° : 4.
- 7.** Cellule selon la revendication 5 ou la revendication 6, dans laquelle la séquence de polynucléotides codant pour Ero1 code pour la séquence polypeptidique donnée dans la SEQ ID n° : 3.
- 25 **8.** Cellule selon l'une quelconque des revendications 1 à 7, dans laquelle la séquence de polynucléotides codant pour XBP1 code pour une XBP1 humaine, de souris ou de hamster.
- 30 **9.** Cellule selon la revendication 8, dans laquelle la séquence de polynucléotides codant pour XBP1 code pour une XBP1 humaine et comprend la séquence donnée dans la SEQ ID n° : 2.
- 10.** Cellule selon la revendication 8 ou la revendication 9, dans laquelle la séquence de polynucléotides codant pour XBP1 code pour une XBP1 humaine et code pour la séquence polypeptidique donnée dans la SEQ ID n° : 1.
- 35 **11.** Cellule selon l'une quelconque des revendications précédentes, la cellule comprenant en outre une séquence de polynucléotides codant pour une protéine d'intérêt.
- 12.** Cellule selon la revendication 11, dans laquelle la protéine d'intérêt est un anticorps ou un fragment de liaison à un antigène de celui-ci.
- 40 **13.** Cellule selon l'une quelconque des revendications précédentes, dans laquelle la cellule est une cellule de mammifère.
- 14.** Cellule selon la revendication 13, la cellule étant une cellule CHO.
- 45 **15.** Lignée de cellules CHOSXE telle qu'ayant fait l'objet d'un dépôt le 10 février 2010 (identification du déposant au complet : CHOS.Xbp1.Ero1a), auprès du European Collection of Cell Cultures (ECACC), HPA, Royaume Uni, sous le numéro de référence des collections de cultures HPA : Q8515, et le numéro d'ordre : 10021001 selon le Traité de Budapest.
- 50 **16.** Procédé de modification d'une cellule hôte pour augmenter la capacité de la cellule hôte à exprimer une protéine, comprenant l'augmentation des niveaux d'expression d'un polypeptide Ero1 ou d'un variant de celui-ci, qui conserve substantiellement la fonction d'Ero1, et d'un polypeptide XBP1 ou d'un variant de celui-ci, qui conserve substantiellement la fonction de XBP1, dans la cellule hôte par rapport aux niveaux d'expression d'Ero1 et de XBP1 dans une cellule non modifiée, le procédé comprenant la transfection de la cellule avec un ou plusieurs polynucléotide(s), tel(s) que défini(s) dans l'une quelconque des revendications 1 à 10.
- 55 **17.** Procédé selon la revendication 16, le procédé comprenant une étape supplémentaire de culture de la cellule modifiée

EP 2 396 410 B1

dans un milieu pour exprimer par ce moyen des taux accrus de polypeptide Ero1 ou d'un variant de celui-ci, qui conserve substantiellement la fonction d'Ero1 ; et de polypeptide XBP1 ou d'un variant de celui-ci, qui conserve substantiellement la fonction de XBP1, en comparaison avec une cellule non modifiée.

- 5 **18.** Procédé selon la revendication 17, le procédé comprenant en outre les étapes suivantes :
- a. choisir un ou plusieurs clone(s) de cellules modifiées ;
 - b. mesurer la quantité d'ARNm d'Ero1 et/ou de protéine dans le(s) un ou plusieurs clone(s) de cellules choisi(s) ;
 - 10 c. mesurer la quantité d'ARNm de XBP1 et/ou de protéine dans le(s) un ou plusieurs clone(s) choisi(s) ;
 - d. comparer la quantité d'ARNm d'Ero1 et/ou de protéine ainsi que d'ARNm de XBP1 et/ou de protéine avec la quantité d'ARNm d'Ero1 et/ou de protéine ainsi que d'ARNm de XBP1 et/ou de protéine dans un clone de cellules non modifiées ; et
 - e. choisir un ou plusieurs clone(s) de cellules modifiées ayant une quantité plus élevée d'ARNm d'Ero1 et/ou de protéine ainsi que d'ARNm de XBP1 et/ou de protéine en comparaison avec le clone de cellules non modifiées.
- 15 **19.** Procédé selon l'une quelconque des revendications 16 à 18, le procédé comprenant en outre la transfection de la cellule hôte avec une séquence de polynucléotides codant pour une protéine d'intérêt et l'expression de la protéine d'intérêt.
- 20 **20.** Procédé de production d'une protéine recombinante d'intérêt comprenant l'expression de la protéine recombinante d'intérêt dans une cellule hôte modifiée, dans laquelle les niveaux d'expression des XBP1 et Ero1 sont accrus par rapport aux niveaux d'expression d'Ero1 et de XBP1 dans une cellule non modifiée, dans lequel la cellule hôte est telle que définie dans l'une quelconque des revendications 11 à 15.
- 25 **21.** Polynucléotide isolé comprenant une séquence de polynucléotides codant pour Ero1 ou un variant de celle-ci, qui conserve substantiellement la fonction d'Ero1 ; et une séquence de polynucléotides codant pour XBP1 ou un variant de celle-ci, qui conserve substantiellement la fonction de XBP1.
- 30 **22.** Polynucléotide isolé selon la revendication 21, le polynucléotide comprenant en outre une séquence de polynucléotides codant pour une protéine d'intérêt.
- 23.** Cassette d'expression comprenant le polynucléotide tel que défini dans l'une quelconque des revendications 21 à 22.
- 35 **24.** Vecteur comprenant le polynucléotide, tel que défini dans l'une quelconque des revendications 21 à 22, ou une cassette d'expression telle que définie dans la revendication 23.
- 40 **25.** Système d'expression comprenant une séquence de polynucléotides recombinante codant pour Ero1 ou un variant de celle-ci, qui conserve substantiellement la fonction d'Ero1 ; une séquence de polynucléotides recombinante codant pour XBP1 ou un variant de celle-ci, qui conserve substantiellement la fonction de XBP1 ; et un milieu ; le système d'expression comprenant un polynucléotide tel que défini dans l'une quelconque des revendications 21 à 22, une cassette d'expression telle que définie dans la revendication 23 ou un vecteur tel que défini dans la revendication 24.
- 45 **26.** Système d'expression selon la revendication 25, le système d'expression comprenant les polynucléotides Ero1 et XBP1 tels que définis dans la revendication 3.
- 27.** Système d'expression selon l'une quelconque des revendications 25 ou 26, le système d'expression comprenant une cellule telle que définie dans l'une quelconque des revendications 1 à 15.
- 50 **28.** Polynucléotide tel que défini dans l'une quelconque des revendications 21 à 22, cassette d'expression telle que définie dans la revendication 23, vecteur tel que défini dans la revendication 24, cellule telle que définie dans l'une quelconque des revendications 1 à 15, ou système d'expression tel que défini dans l'une quelconque des revendications 25 ou 26, pour être utilisé(e) comme médicament.
- 55 **29.** Utilisation d'une séquence de polynucléotides recombinante codant pour Ero1, comprenant la séquence polypeptidique donnée dans la SEQ ID n° : 3, et une séquence de polynucléotides recombinante codant pour XBP1, comprenant la séquence polypeptidique donnée dans la SEQ ID n° : 1, pour exprimer une protéine d'intérêt.

Figure 1

(a) Amino acid sequence of the spliced form of human XBP1 (SEQ ID NO: 1)

MVVVAAAPNPADGTPKVLLLSGQPASAAGAPAGQALPLMVPAQRGASPEAAASGG
LPQARKRQRLTHLSPEEKALRRKLNKRVAAQTARDRKKARMSELEQQVVDLEEE
NQKLLLENQLLREKTHGLVVENQELRQRLGMDALVAEEEEAEAKGNEVRPVAGSA
ESAAGAGPVVTPPEHLPMDSSGIDSSDSESDILLGILDNLDPMFFKCPSPASLEE
LPEVYPEGPSSLPASLSVGTSSAKLEAINELIRFDHIYTKPLVLEIPSETESQANVV
VKIEEAPLSPENDHPEFIVSVKEEPVEDDLVPELGISNLLSSSHCPKPSSCLLDAYS
DCGYGGSLSPFSDMSSLLGVNHSWEDTFANELFPQLISV*

(b) Nucleic acid sequence of the spliced form of human XBP1 (SEQ ID NO: 2)

atggtggtggtggcagccgcgccgaacccggccgacgggaccctaaagtctgcttctgctggggcagccgcctccgccgc
cggagccccggccggccaggccctgccgctcatggtgccagccagagagggccagccggaggcagcgagcggggggg
ctgcccaggcgcgcaagcgacagcgcctcacgcacctgagccccaggagaaggcgctgaggaggaaactgaaaaacaga
gtagcagctcagactgccagagatcgaagaaggctcgaatgagtgagctggaacagcaagtggtagattagaagaagaaa
ccaaaaacttttctagaaaatcagcttttacgagagaaaactcatggccttgtagttgagaaccaggagttaagacagcgttggg
gatggatgccctggttctgaagaggaggcggaagccaaggggaatgaagtgagccagtggccgggtctgctgagtcgca
gcaggtgcaggcccagttgtcacccctccagaacatcctccatggattctggcgggtattgactcttcagattcagagctgatacc
tgttgggcattctggacaacttgaccagctcatgttctcaaatgccttccccagagcctgccagcctggaggagctcccagagg
tctaccagaaggaccagttccttaccagcctcccttctctgctcagtggggagctcatcagccaagctggaagccattaatgaact
aatcgttttgaccacatatataccaagcccctagtcttagagataccctctgagacagagagccaagctaattggtagtgaaaatc
gaggaagcacctctcagcccctcagagaatgacacctgaattcattgtctcagtgaggagaacctgtagaatgacctcgtt
ccggagctgggtatctcaaatctgcttcatccagccactgcccgaagccatcttctgcctactggatgcttacagtactgttgata
cgggggttcccttccccattcagtgacatgtcctctctgcttgggtgtaaacattcttggaggagacttttgcaatgaactcttccc
cagctgattagtgtctaa

Figure 2

(a) Amino acid sequence of human Ero1alpha (SEQ ID NO: 3)

MGRGWGFLFLLGAVWLLSSGHGEEQPPETAARCFQCQVSGYLDDCTCDVETID
 RFNNYRLFRLQKLLSDYFRYYKVNLRPCPFWNDISQCGRRDCAVKPCQSDEV
 PDGIKSASYKYSEEANNLIEECEQAERLGAVDESLSEETQKAVLQWTKHDDSSDNF
 CEADDIQSPEAEYVDLLLNPERYTGYKGPDAWKIWNVIYEENCFKPQTIKRPLNPL
 ASGQGTSEENTFYSWLEGLCVEKRAFYLISGLHASINVHLSARYLLQETWLEKK
 WGHNITEFQQRFDGILTEGEGPRRLKNLYFLYLIELRALSKVLPFFERPDFQLFTGN
 KIQDEENKMLLLEILHEIKSFPLHFDETSFFAGDKKEAHKLKEDFRLHFRNISRIMD
 CVGCFKRLWGNLQTQGLGTALKILFSEKLIANMPESGPSYEFHLTRQEIVSLFNAF
 GRISTSVKELENFRNLLQNIH*

(b) Nucleic acid sequence of human Ero1alpha (SEQ ID NO: 4)

atgggccgcggtggggattctgtttggcctcctgggcgccgtgtggctgctcagctcgggccacggagaggagcagcccccg
 gagacagcggcacagaggtgcttctgccaggtagtggtacttgatgattgtacctgtgatgtgaaccattgatagattataa
 ctacaggctttccaagactacaaaaacttctgaaagtactacttaggtattacaaggtaaacctgaagaggccgtgctcttctg
 gaatgacatcagccagtgtggaagaaggactgtgctgtcaaacatgtcaatctgatgaagttctgatggaattaaatctgcgag
 ctacaagtattctgaagaagccaataatctcattgaagaatgtgaacaagctgaacgacttgagcagtgatgaatctctgagtga
 ggaaacacagaaggctgttctcagtggaaccaagcatgatgattctcagataactctgtgaagctgatgacattcagtcacctgaa
 gctgaatatgtagattgcttcttaactctgagcgtactggttacaaggaccagatgcttgaaaaatggaatgcatctacga
 agaaaactgtttaagccacagacaattaaagaccttaaatccttggcttctggtcaagggacaagtgagagaacacttttaca
 gttggctagaaggctctgtgtagaaaaagagcattctacagacttatatctggcctacatgcaagcattaatgtgcattgagtga
 agatattttacaagagacctggttagaaaagaatggggacacaacattacagaattcaacagcgatttgatggaatttgactga
 aggagaaggccaagaaggcttaagaactgtatttctacttaatagaactaaggcttatccaaagtgtaccattctcgagcg
 ccagatttcaactcttactggaataaaaatcaggatgaggaaaacaaaatgttactctggaaatactcatgaaatcaagtcattt
 ccttgcatttgatgagacttcatttttctggggataaaaaagaacacacaactaaaggaggacttgcactgcattttagaaat
 attcaagaattatggattgtgtggtgttttaaatgtcgtctgtggggaaatctcagactcagggttggcactgctctgaagatctt
 atttctgagaaattgatagcaaatatgccagaaagtggacctagttagttccatcaccagacaagaatagtatcattattcaa
 cgatttgaagaatttctacaagtgtaagaattagaaaacttcaggaactgttacagaatattcattaa




Figure 3a



Figure 3b




Figure 4




Figure 5





Figure 7







Figure 8






Figure 10




Figure 11

Figure 12a
mAb 42




Figure 12b
mAb 61




Figure 12c
mAb 164




Figure 13





Figure 14

		mAb 42		mAb 61		mAb 164		Average	
		CHOS	CHOS XE	CHOS	CHOS XE	CHOS	CHOS XE	CHOS	CHOS XE
	G0F	47	53	37	48	49	50	44	50
	G1F	21	10	17	11	24	18	21	13
	G2F	2	0	1	0	1	1	2	1
	M3N3F	1	1	1	2	1	2	1	2
	M3N2F	1	0	0	0	0	0	0	0
	G0	7	22	11	26	10	16	9	21
	G1	9	5	17	5	6	8	11	6
	G2	0	1	6	1	2	1	3	1
	M3N3	0	3	1	1	0	2	0	2
	M3N2	1	0	1	0	0	0	0	0
	M5	9	5	8	5	6	2	8	4
	M6	2	1	0	0	0	0	1	0
	M7	0	0	0	0	0	0	0	0
	M8	0	0	0	0	0	0	0	0
	M9	0	0	0	0	0	0	0	0
	Fucosylated	72	65	55	62	76	71	68	66
	Non-fucosylated	17	30	36	33	18	27	24	30
	High mannose	11	5	9	5	6	2	9	4



REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 6361964 B [0005]
- WO 9907727 A [0007]
- WO 2008115596 A [0008]
- WO 2006067511 A [0009]
- WO 2004111194 A [0012]
- WO 2006028889 A [0012]
- US 20050250182 A [0012]
- GB 0902180 A [0171]

Non-patent literature cited in the description

- **MEZGHRANI et al.** *EMBO Journal*, 2001, vol. 20 (22), 6288-6296 [0004]
- **GUNN et al.** *Molecular Immunology*, 2004, vol. 41, 919-9927 [0006]
- **LEE et al.** *Molecular and Cellular Biology*, 2003, vol. 23 (21), 7448-7459 [0010]
- **TIGGES M et al.** Xbp1-based engineering of secretory capacity enhances the productivity of Chinese hamster ovary cells. *Metabolic Engineering*, 2006, vol. 8 (3), 264-272 [0011]
- **DEAVEN, L.L. et al.** *Chromasoma*, 1973, vol. 41, 129 [0046]
- **D'ANNA, J.A. et al.** *Methods in Cell Science*, 1996, vol. 18, 115 [0046]
- **D'ANNA, J.A. et al.** *Radiation Research*, 1997, vol. 148, 260 [0046]
- **PUCK, T. et al.** Genetics of Somatic Mammalian Cells IV Properties of Chinese Hamster Cell Mutants With Respect To The Requirement For Proline. *Genetics*, March 1967, vol. 55, 513-524 [0046]
- Computational Molecular Biology. Oxford University Press, 1988 [0054]
- Biocomputing. Informatics and Genome Projects. Academic Press, 1993 [0054]
- Computer Analysis of Sequence Data. Humana Press, 1994 [0054]
- **VON HEINJE, G.** Sequence Analysis in Molecular Biology. Academic Press, 1987 [0054]
- Sequence Analysis Primer. M Stockton Press, 1991 [0054]
- **YOSHIDA et al.** *Cell*, 2001, vol. 107, 881-891 [0058]

ELJÁRÁS FEHÉRJE ELŐÁLLÍTÁSÁRA

Szabadalmi igénypontok

1. Rekombináns gazdasejt, amelyben a sejt úgy módosított, hogy tartalmaz SEQ ID NO: 3 szerinti megadott szekvenciájú polipeptidet tartalmazó Ero1-et vagy annak az Ero1 funkcióját lényegében megtartó változatát kódoló exogén polinukleotid-szekvenciát; valamint SEQ ID NO: 1 szerinti megadott szekvenciájú polipeptidet tartalmazó XBP1-et vagy annak az XBP1 funkcióját lényegében megtartó változatát kódoló exogén polinukleotid-szekvenciát,

és a módosított gazdasejtnek fokozott Ero1 és XBP1 expressziós szintjei vannak egy módosítatlan sejtben jelen lévő Ero1 és XBP1 expressziós szintekhez képest.

2. Az 1. igénypont szerinti sejt, ahol a sejt Ero1- és XBP1-polinukleotidot tartalmaz, amelyek tartalmazzák mind az Ero1-et vagy az Ero1-funkciót lényegében megtartó változatát kódoló polinukleotid-szekvenciát, mind az XBP1-et vagy az XBP1-funkciót lényegében megtartó változatát kódoló polinukleotid-szekvenciát.

3. Az 1. igénypont szerinti sejt, ahol a sejt tartalmaz Ero1-et vagy az Ero1-funkciót lényegében megtartó változatát kódoló polinukleotid-szekvenciát tartalmazó Ero1-polinukleotidot és külön XBP1-et vagy az XBP1-funkciót lényegében megtartó változatát kódoló polinukleotid-szekvenciát tartalmazó XBP1-polinukleotidot.

4. Az 1-3. igénypontok bármelyike szerinti sejt, amelyben az Ero1-et kódoló polinukleotid-szekvencia humán, egér- vagy hörsőg-Ero1-et kódol.

5. A 4. igénypont szerinti sejt, amelyben az Ero1-et kódoló polinukleotid-szekvencia humán Ero1- α vagy Ero1- β .

6. Az 5. igénypont szerinti sejt, amelyben az Ero1-et kódoló polinukleotid-szekvencia Ero1- α -t kódol és a SEQ ID NO: 4 szerinti megadott szekvenciát tartalmaz.

7. Az 5. vagy 6. igénypont szerinti sejt, amelyben az Ero1-et kódoló polinukleotid-szekvencia a SEQ ID NO: 3 szerinti megadott polipeptid-szekvenciát kódolja.

8. Az 1-7. igénypontok bármelyike szerinti sejt, amelyben az XBP1-et kódoló polinukleotid-szekvencia humán, egér- vagy hörsőg-XBP1-et kódol.

9. A 8. igénypont szerinti sejt, amelyben az XBP1-et kódoló polinukleotid-szekvencia humán XBP1-et kódol, és tartalmazza a SEQ ID NO: 2 szerinti megadott szekvenciát.

10. A 8. vagy 9. igénypont szerinti sejt, amelyben az XBP1-et kódoló polinukleotid-szekvencia humán XBP1-et kódol, és a SEQ ID NO: 1 szerinti megadott polipeptid-szekvenciát kódol.

11. Bármely megelőző igénypont szerinti sejt, ahol a sejt tartalmaz továbbá egy jelentőséggel bíró fehérjét kódoló polinukleotid-szekvenciát is.



SZTNH-100052601

12. A 11. igénypont szerinti sejt, amelyben a jelentőséggel bíró fehérje antitest vagy annak antigénkötő fragmense.

13. Bármely megfelelő igénypont szerinti sejt, ahol a sejt említséjt.

14. A 13. igénypont szerinti sejt, ahol a sejt CHO-sejt.

15. CHOSXE-sejtvonal (a letétbe helyező teljes azonosítója: CHOS.Xbpl.Ero1a), amely 2010. február 10-én lett letétbe helyezve az Európai Sejtenyésztetek Gyűjteményénél (European Collection of Cell Cultures (ECACC), HPA, Egyesült Királyság) a következő HPA tenyésztetgyűjteményi hivatkozási számon: Q8515 és a következő nyilvántartási számon: 10021001 a Budapesti Szerződéssel összhangban.

16. Eljárás gazdasejt módosítására a gazdasejt fehérjeexpressziós képességének fokozására, amely tartalmazza Ero1-polipeptid vagy Ero1-funkciót lényegében megtartó változata és XBP1-polipeptid vagy XBP1-funkciót lényegében megtartó változata expressziós szintjének fokozását a gazdasejtben, egy módosítatlan sejtben jelen lévő Ero1 és XBP1 expressziós szintekhez képest, ahol az eljárás tartalmazza a sejt transzfektálását egy vagy több, 1-10. igényponti bármelyikében meghatározott polinukleotiddal.

17. A 16. igénypont szerinti eljárás, ahol az eljárás további lépésként tartalmazza a módosított sejt tenyésztését tápközegben, miáltal Ero1-polipeptid vagy Ero1-funkciót lényegében megtartó változata és XBP1-polipeptid vagy XBP1-funkciót lényegében megtartó változata fokozott szinteken expresszálódnak egy módosítatlan sejthez képest.

18. A 17. igénypont szerinti eljárás, ahol az eljárás tartalmazza továbbá a következő lépéseket:

- a. egy vagy több, módosított sejtklón szelektálása;
- b. Ero1 mRNS és/vagy fehérje mennyiségének mérése a kiválasztott egy vagy több sejtklónban;
- c. XBP1 mRNS és/vagy fehérje mennyiségének mérése a kiválasztott egy vagy több klónban;
- d. az Ero1 mRNS és/vagy fehérje mennyiségének és az XBP1 mRNS és/vagy fehérje mennyiségének összehasonlítása Ero1 mRNS és/vagy fehérje és XBP1 mRNS és/vagy fehérje mennyiségével egy módosítatlan sejtklónban; és
- e. egy vagy több módosított sejtklón kiválasztása, amelyben a módosítatlan sejtklónhoz képest az Ero1 mRNS és/vagy fehérje mennyisége és az XBP1 mRNS és/vagy fehérje mennyisége nagyobb.

19. A 16-18. igénypontok bármelyike szerinti eljárás, ahol az eljárás tartalmazza továbbá gazdasejt transzfektálását jelentőséggel bíró fehérjét kódoló polinukleotid-szekvenciával, és a jelentőséggel bíró fehérje expresszálását.

20. Eljárás jelentőséggel bíró, rekombináns fehérje előállítására, amely tartalmazza a jelentőséggel bíró, rekombináns fehérje expresszálását módosított gazdasejtben, amelyben az XBP1 és az Ero1 expressziós szintjei megnövekedtek Ero1 és XBP1 expressziós szintjeihez képest egy módosítatlan sejtben, ahol a gazdasejt a 11-15. igénypontok bármelyike szerint meghatározott gazdasejt.

21. Izolált polinukleotid, amely tartalmaz Ero1-et vagy Ero1-funkciót lényegében megtartó változatát kódoló polinukleotid-szekvenciát, valamint XBP1-et vagy XBP1-funkciót lényegében megtartó változatát kódoló polinukleotid-szekvenciát, ahol a polinukleotid 4-10. igénypontok bármelyike szerinti polinukleotid.

22. A 21. igénypont szerinti izolált polinukleotid, amelyben a polinukleotid tartalmaz továbbá jelentőséggel bíró fehérjét kódoló polinukleotid-szekvenciát.

23. Expressziós egység, amely a 21-22. igénypontok bármelyike szerint meghatározott polinukleotidot tartalmaz.

24. Vektor, amely a 21-22. igénypontok bármelyike szerint meghatározott polinukleotidot vagy a 23. igénypont szerinti meghatározott expressziós egységet tartalmaz.

25. Expressziós rendszer, amely tartalmaz Ero1-et vagy Ero1-funkciót lényegében megtartó változatát kódoló polinukleotid-szekvenciát kódoló rekombináns polinukleotid-szekvenciát, valamint XBP1-et vagy XBP1-funkciót lényegében megtartó változatát kódoló rekombináns polinukleotid-szekvenciát; valamint tápközeget; ahol az expressziós rendszer tartalmaz 21-22. igénypontok bármelyike szerint meghatározott polinukleotidot, a 23. igénypont szerinti meghatározott expressziós egységet vagy a 24. igénypont szerinti meghatározott vektort.

26. A 25. igénypont szerinti expressziós rendszer, ahol az expressziós rendszer tartalmazza a 3. igénypont szerint meghatározott Ero1- és XBP1-polinukleotidokat.

27. A 25. vagy 26. igénypontok bármelyike szerinti expressziós rendszer, ahol az expressziós rendszer 1-15. igénypontok bármelyike szerint meghatározott sejtet tartalmaz.

28. A 21-22. igénypontok bármelyike szerint meghatározott polinukleotid, a 23. igénypont szerinti meghatározott expressziós egység, a 24. igénypont szerint meghatározott vektor, az 1-15. igénypontok bármelyike szerint meghatározott sejt vagy a 25. vagy 26. igénypontok bármelyike szerint meghatározott expressziós rendszer gyógyszerként történő alkalmazásra.

29. SEQ ID NO: 3 szerint megadott polipeptid-szekvenciát tartalmazó Ero1-et kódoló rekombináns polinukleotid-szekvencia; valamint SEQ ID NO: 1 szerint megadott polipeptid-szekvenciát tartalmazó XBP1-et kódoló rekombináns polinukleotid-szekvencia alkalmazása jelentőséggel bíró fehérje expresszáálására.